var title_f34_63_35824="Epinephrine (adrenaline): Drug information";
var content_f34_63_35824=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Epinephrine (adrenaline): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <div class=\"block inc\" id=\"F12624536\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <p>",
"     Information for this drug is presented separately based upon the following methods of administration:",
"    </p>",
"   </div>",
"   <div class=\"sec_xr rmolist\" id=\"F12624537\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <ul xmlns=\"\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?3/34/3620?source=see_link\">",
"       Epinephrine (adrenaline) (nasal): Drug information",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?11/4/11337?source=see_link\">",
"       Epinephrine (adrenaline) (systemic therapy and oral inhalation): Drug information",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9409 Version 30.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-61.234.146.186-869C284B9E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_63_35824=[""].join("\n");
var outline_f34_63_35824=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   DRUG INFORMATION",
"   <br/>",
"   [by method of administration]",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?3/34/3620?source=related_link\">",
"      Epinephrine (adrenaline) (nasal): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?11/4/11337?source=related_link\">",
"      Epinephrine (adrenaline) (systemic therapy and oral inhalation): Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_63_35825="Delayed presentation of metatarsal shaft fracture";
var content_f34_63_35825=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F73984&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F73984&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 506px\">",
"   <div class=\"ttl\">",
"    Delayed presentation of metatarsal shaft fracture",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 486px; height: 468px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The first metatarsal fracture (white arrow) was evident on the initial and follow-up radiographs (panels A and B), but the second metatarsal fracture (black arrow) only clearly appeared with a follow-up film (panel B).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Robert L Hatch, MD, MPH and James R Clugston, MD, MS.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_63_35825=[""].join("\n");
var outline_f34_63_35825=null;
var title_f34_63_35826="Ciprofloxacin and hydrocortisone: Drug information";
var content_f34_63_35826=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Ciprofloxacin and hydrocortisone: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?1/26/1444?source=see_link\">",
"    see \"Ciprofloxacin and hydrocortisone: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?6/35/6706?source=see_link\">",
"    see \"Ciprofloxacin and hydrocortisone: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F151824\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Cipro&reg; HC",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F151825\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Cipro&reg; HC",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F151835\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antibiotic/Corticosteroid, Otic",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F151826\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Otitis externa: Otic: The recommended dosage for all patients is three drops of the suspension in the affected ear twice daily for 7 days; twice-daily dosing schedule is more convenient for patients than that of existing treatments with hydrocortisone, which are typically administered 3 or 4 times a day; a twice-daily dosage schedule may be especially helpful for parents and caregivers of young children",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F151831\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?6/35/6706?source=see_link\">",
"      see \"Ciprofloxacin and hydrocortisone: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Children &ge;1 year: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F151827\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15794428\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15794429\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F151817\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Suspension, otic:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cipro&reg; HC: Ciprofloxacin hydrochloride 0.2% and hydrocortisone 1% (10 mL) [contains benzyl alcohol]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F151809\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F151818\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of acute otitis externa, sometimes known as &ldquo;swimmer's ear&rdquo;",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F13881558\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     1% to 10%: Central nervous system: Headache (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &lt;1% (Limited to important or life-threatening): Alopecia, fungal dermatitis, hypersensitivity reactions, migraine, paresthesia",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F151832\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F151814\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F9624500\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F14287198\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted with this combination. Refer to individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F14287201\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F14287200\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known if serum levels of ciprofloxacin or hydrocortisone are high enough following otic administration to produce detectable quantities in breast milk. Refer to individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F151821\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension",
"     </b>",
"     (Cipro HC Otic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.2-1% (10 mL): $190.20",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F151822\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Ciflox (DK);",
"     </li>",
"     <li>",
"      Cipro HC (BR);",
"     </li>",
"     <li>",
"      Cipro HC Otic (HK);",
"     </li>",
"     <li>",
"      Ciprobay HC (EE, KP, SG, ZA);",
"     </li>",
"     <li>",
"      Ciproxin HC (CH);",
"     </li>",
"     <li>",
"      Ciproxin HC ear drops (AU);",
"     </li>",
"     <li>",
"      Ciproxin HC Otic Drops (NZ);",
"     </li>",
"     <li>",
"      Ciriax Otic (AR, PE);",
"     </li>",
"     <li>",
"      Fixamicin HC (CO);",
"     </li>",
"     <li>",
"      Otalex (VE);",
"     </li>",
"     <li>",
"      Otex HC (CN, PY, UY);",
"     </li>",
"     <li>",
"      Oto Eni (MX);",
"     </li>",
"     <li>",
"      Otodrops (EC);",
"     </li>",
"     <li>",
"      Otosec HC (CO, DO, GT, PA, PE);",
"     </li>",
"     <li>",
"      Quinotic HC (VE);",
"     </li>",
"     <li>",
"      Siproxan (TW)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F151820\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8873 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-222.190.118.195-1E1E8CC54B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_63_35826=[""].join("\n");
var outline_f34_63_35826=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F151824\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F151825\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F151835\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F151826\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F151831\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F151827\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15794428\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15794429\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F151817\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F151809\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F151818\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13881558\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F151832\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F151814\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9624500\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14287198\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14287201\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14287200\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F151821\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F151822\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F151820\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8873\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8873|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?1/26/1444?source=related_link\">",
"      Ciprofloxacin and hydrocortisone: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?6/35/6706?source=related_link\">",
"      Ciprofloxacin and hydrocortisone: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_63_35827="Conduction system action potentials";
var content_f34_63_35827=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F61989&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F61989&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Action potentials generated by different parts of conduction system",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 305px; height: 464px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The sinoatrial (SA) and atrioventricular (AV) nodes generate a slow action potential, mediated by calcium ions. In comparison, the tissues of the atria, ventricles, and the His-Purkinje system generate a fast action potential mediated by sodium ions. Sequential activation of these structures results in the characteristic waveforms visible on the surface ECG. The AV node and bundle of His are small structures; as a result, no electrical activity is recorded on the surface ECG during their activation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_63_35827=[""].join("\n");
var outline_f34_63_35827=null;
var title_f34_63_35828="Hailey Hailey";
var content_f34_63_35828=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F80862&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F80862&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Vulvar Hailey-Hailey disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 313px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Lynne J Margesson, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_63_35828=[""].join("\n");
var outline_f34_63_35828=null;
var title_f34_63_35829="Visual inspect lugols";
var content_f34_63_35829=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F56093&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F56093&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Visual inspection with Lugol's iodine (VILI)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 401px; height: 607px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: IARC screening group. Testing and reporting the results of visual inspection with Lugol's iodine (VILI). In: Sankaranarayanan R, Wesley RS. A practical manual on visual screening for cervical neoplasia. IARC Press, Lyon, 2003. Copyright &copy; 2003 IARC Press.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_63_35829=[""].join("\n");
var outline_f34_63_35829=null;
var title_f34_63_35830="Brain MRI 2 year old with Krabbe disease";
var content_f34_63_35830=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F52319&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F52319&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 482px\">",
"   <div class=\"ttl\">",
"    Brain MRI of a 2 year old with Krabbe disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 462px; height: 583px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Brain MRI of a child age 2 years who presented with visual loss, showing&nbsp;axial T2 images from the level of the midbrain (A) to the thalamus (C).&nbsp;&nbsp;There is increased signal in the periventricular and deep white matter, predominantly involving the occipital and parietal lobes.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Dr. Patricia Duffner.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_63_35830=[""].join("\n");
var outline_f34_63_35830=null;
var title_f34_63_35831="Metastatic breast cancer: Local treatment";
var content_f34_63_35831=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Metastatic breast cancer: Local treatment",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/63/35831/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/63/35831/contributors\">",
"     Michael S Sabel, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/63/35831/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/63/35831/contributors\">",
"     Daniel F Hayes, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/63/35831/contributors\">",
"     Deputy Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/63/35831/contributors\">",
"     Don S Dizon, MD, FACP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/63/35831/contributors\">",
"     Rosemary B Duda, MD, MPH, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?34/63/35831/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 2, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A small but important subset of patients with metastatic breast cancer have limited systemic tumor burden and biologically indolent disease. They represent less than five percent of patients with newly diagnosed metastatic breast cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/63/35831/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. However, for such patients, an intensified multidisciplinary approach combining systemic therapies with surgery, radiation, and regional chemotherapy may not only prevent local complications, but prolong survival.",
"   </p>",
"   <p>",
"    Local treatment of breast cancer metastases is reviewed here. Systemic therapy and general principles of management of metastatic breast cancer, including treatment of the breast primary in the metastatic setting, treatment of brain and bone metastases, and management of locoregionally recurrent breast cancer are discussed separately.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?7/11/7354?source=see_link\">",
"       \"Systemic treatment for metastatic breast cancer: General principles\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?19/0/19464?source=see_link\">",
"       \"Management of brain metastases in breast cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?7/54/8042?source=see_link\">",
"       \"Osteoclast inhibition in the management of bone metastases from breast cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?4/12/4292?source=see_link\">",
"       \"Role of breast surgery for stage IV breast cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/45/30426?source=see_link\">",
"       \"Management of locoregional recurrence of breast cancer after mastectomy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/53/34650?source=see_link\">",
"       \"Management of locoregional recurrence of breast cancer after breast conserving therapy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/21/43352?source=see_link\">",
"       \"Axillary node metastases with occult primary breast cancer\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36512206\">",
"    <span class=\"h1\">",
"     RATIONALE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The median survival for patients with metastatic (stage IV) breast cancer is 18 to 24 months, although the range extends from only a few months to many years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/63/35831/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. The few patients who experience long-term survival tend to be young with an excellent performance status and limited metastatic disease. For such patients, an intensified multidisciplinary approach combining systemic therapies with local treatment (surgery, radiation, and regional chemotherapy) may not only prevent local complications, but prolong survival.",
"   </p>",
"   <p>",
"    Several retrospective series, as described below, have suggested that patients with metastatic breast cancer treated with local treatment for the primary tumor or distant metastases achieve long-term survival. However, interpretation of these results is limited by bias, including selection bias and reporting bias. Patients selected for surgery are younger, with less disseminated disease and less visceral metastases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/63/35831/abstract/6\">",
"     6",
"    </a>",
"    ]. Patients with significant comorbidities are not recommended for intensive therapies, whereas patients selected for surgery are often those who have good prognostic features and indolent biologic behavior. Local treatment has not been compared to systemic therapy or supportive care in randomized trials. Furthermore, it is unknown how advances in systemic therapy [such as human epidermal growth factor receptor 2 (HER2)-directed therapies], impact upon previously reported benefits from local therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     SELECTION OF PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The selection of appropriate candidates for surgical intervention requires a thorough assessment of the patient's medical condition, extent and clinical behavior of the breast cancer, and the feasibility of resecting the metastasis with a negative margin. The relative risks and benefits of surgery must be weighed for each individual patient.",
"   </p>",
"   <p>",
"    Several factors that are predictive of outcome may help in the selection of appropriate patients for surgical consideration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Performance status and comorbidity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Perhaps the most important issues in choosing patients for local treatment of metastatic disease are the performance status and an estimation of the relative risks of a planned operation. Patients with an Eastern Cooperative Oncology Group (ECOG) performance status of 2 or worse (",
"    <a class=\"graphic graphic_table graphicRef72901 \" href=\"mobipreview.htm?9/15/9467\">",
"     table 1",
"    </a>",
"    ) or those with significant medical comorbidity should be considered carefully for local treatment, especially surgery, as they are likely to have high rates of postoperative morbidity and mortality.",
"   </p>",
"   <p>",
"    Patients evaluated for lung resection should have a complete pulmonary evaluation, while those being considered for liver resection should have relatively preserved liver function. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/2/15400?source=see_link\">",
"     \"Preoperative evaluation for lung resection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Oligometastatic disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multivariable analysis of local treatment outcomes suggest that those patients with limited metastatic disease, ie, solitary or few detectable lesions (oligometastatic disease) and limited to a single organ are more likely to benefit from local therapy than those with multiple metastases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/63/35831/abstract/6-10\">",
"     6-10",
"    </a>",
"    ]. One exception is solitary bone disease, as a few studies found no difference in long-term outcomes in patients undergoing hepatic resection in the presence or absence of extrahepatic disease (predominantly bone) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/63/35831/abstract/11-13\">",
"     11-13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Many of the studies that report successful surgery for metastatic disease (discussed below) limited enrollment to patients with single organ involvement. Patients being considered for local therapy should undergo a thorough restaging evaluation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/49/10009?source=see_link\">",
"     \"Clinical features, diagnosis, and staging of newly diagnosed breast cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36513457\">",
"    <span class=\"h2\">",
"     Disease-free interval",
"    </span>",
"    &nbsp;&mdash;&nbsp;A long disease-free interval (DFI, the period of time between the diagnosis of breast cancer and the development of distant metastases) is associated with a better outcome with local therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/63/35831/abstract/14-16\">",
"     14-16",
"    </a>",
"    ]. The specific cutoff value of DFI that best discriminates between favorable and unfavorable outcomes is unclear. However, the shorter the DFI, the less likely the patient will benefit from local therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Complete resection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Careful preoperative evaluation is necessary to determine the likelihood that complete resection of the metastatic deposit is feasible. Positive margins are associated with worse outcomes in most but not all series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/63/35831/abstract/7,15,17-19\">",
"     7,15,17-19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36512642\">",
"    <span class=\"h1\">",
"     LOCAL TREATMENT OF SPECIFIC SITES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Resection or other means of local therapy, such as radiation therapy (RT), radiofrequency ablation, or cryotherapy, of isolated metastases has been shown in several small studies (discussed below) to be associated with longer progression-free survival and overall survival than might be otherwise reported for patients with metastatic breast cancer. However, it is not clear if the local therapy is responsible for long-term survival or if these highly selected patients would have done well anyway. With the exception of brain and spinal cord metastases, there are no prospective randomized clinical trials to determine if such approaches improve palliation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    survival.",
"   </p>",
"   <p>",
"    Perhaps the main indication for resection of new isolated metastases, especially pulmonary, hepatic, or abdominopelvic, in a patient with a prior history of breast cancer is diagnostic, since some patients may have a new primary malignancy or a change in tumor marker status. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/11/7354?source=see_link\">",
"     \"Systemic treatment for metastatic breast cancer: General principles\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Thus, the decision to approach a patient with local therapy in the absence of a local emergency, such as impending fracture, must be made on an individual basis, either because it might permit the patient to forgo or delay toxic systemic therapy or because the physician believes that the available uncontrolled data suggest a survival benefit.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Lung metastases",
"    </span>",
"    &nbsp;&mdash;&nbsp;Isolated lung metastases occur in 10 to 25 percent of patients with metastatic breast cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/63/35831/abstract/8,16\">",
"     8,16",
"    </a>",
"    ]. Pulmonary resection or metastasectomy offers an opportunity for long-term survival in highly selected patients with metastatic breast cancer, with cases series demonstrating five-year overall survival ranging from 30 to 80 percent and median survival duration of 40 to 80 months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/63/35831/abstract/7,16,19,20\">",
"     7,16,19,20",
"    </a>",
"    ]. Patients most likely to experience long-term survival after mastectomy are those with solitary metastases and a disease-free interval greater than 36 months. Other prognostic factors may include hormone-receptor status, size of metastases, completeness of resection, and use of anatomic resection (as opposed to wedge resection) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/63/35831/abstract/7,9\">",
"     7,9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pulmonary resection may be diagnostic as well as therapeutic in breast cancer patients, since a significant number of solitary pulmonary nodules in patients with a history of breast cancer are not breast cancer metastases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/63/35831/abstract/19,21,22\">",
"     19,21,22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The differential diagnosis, diagnostic evaluation, and local management of lung metastases, including surgical resection, radiofrequency ablation (RFA), and stereotactic body RT, are discussed separately.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?43/31/44537?source=see_link\">",
"       \"Diagnostic evaluation and management of the solitary pulmonary nodule\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/42/25255?source=see_link\">",
"       \"Radiofrequency ablation of lung tumors\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?16/47/17143?source=see_link\">",
"       \"Stereotactic body radiation therapy for primary and metastatic lung tumors\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Liver metastases",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hepatic metastases occur in over half of patients with metastatic breast cancer. They are most commonly a late development, associated with disseminated disease and a poorer prognosis than bone or soft tissue metastases. Only 5 to 12 percent of patients have isolated liver involvement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/63/35831/abstract/23-25\">",
"     23-25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hepatic resection for breast cancer metastases may be associated with long-term survival in appropriately selected patients. In a systematic review of 19 studies involving 535 patients who underwent hepatectomy for metastatic breast cancer, median overall survival was 40 months (range, 23 to 77 months) with five-year survival following resection of 40 percent (range, 21 to 80 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/63/35831/abstract/26\">",
"     26",
"    </a>",
"    ]. Postoperative mortality ranged from zero to six percent and the complication rate ranged from 0 to 44 percent. Prognostic factors following hepatic resection were positive margins and hormone-refractory disease.",
"   </p>",
"   <p>",
"    The ideal candidate has a solitary metastasis, no evidence of extrahepatic metastatic disease, normal liver function, a good performance status, and a long DFI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/63/35831/abstract/9,11,14\">",
"     9,11,14",
"    </a>",
"    ]. An essential part of the diagnostic work-up in patients who are considered for hepatectomy is precise imaging of the liver (helical computed tomography scan or magnetic resonance imaging) to evaluate whether a complete resection can be achieved while retaining a sufficient volume of functional liver. It is not clear that multiple metastases are a negative prognostic feature for resection of liver metastases, as long as they can be completely resected [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/63/35831/abstract/11,12,17\">",
"     11,12,17",
"    </a>",
"    ]. Bilobar disease and location close to the porta hepatis are typically considered a contraindication to resection. Initial laparoscopic exploration may spare unresectable patients the morbidity of a laparotomy, since up to one-half of patients considered for resection are discovered to have diffuse liver lesions or peritoneal dissemination at the time of laparotomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/63/35831/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hepatic resection is appropriate for highly selected patients, but alternative local therapies are being increasingly used to treat liver metastases. Liver-directed therapy includes radiofrequency ablation (RFA), stereotactic body RT (SBRT), selective internal RT (SIRT), percutaneous ethanol injection, cryotherapy, hepatic arterial infusion chemotherapy, transhepatic arterial chemoembolization (TACE), and interstitial laser therapy. In general, there are fewer less data regarding the use of these techniques for metastatic breast cancer than there are for patients with colorectal cancer liver metastases or primary hepatocellular cancer. Furthermore, none of these methods has been directly compared to systemic chemotherapy in metastatic breast cancer.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Radiofrequency ablation (RFA) can be used alone or in combination with resection [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/63/35831/abstract/28-31\">",
"       28-31",
"      </a>",
"      ]. It is most effective with solitary lesions less than 3 cm in diameter. &nbsp;",
"      <br/>",
"      <br/>",
"      RFA entails the local application of radiofrequency thermal energy to a lesion, in which a high frequency alternating current moves from the tip of an electrode into the tissue surrounding that electrode. As the ions within the tissue attempt to follow the change in the direction of the alternating current, their movement results in frictional heating of the tissue. As the temperature within the tissue becomes elevated beyond 60&ordm; C, cells begin to die, resulting in a region of necrosis surrounding the electrode.",
"     </li>",
"     <li>",
"      Selective internal RT (SIRT or targeted radiotherapy with Yttrium-90 microspheres [SIR-Spheres]) uses millions of microscopic beads injected into the liver to deliver internal radiation directly to the tumor.",
"     </li>",
"     <li>",
"      Interstitial laser therapy (ILT) causes local tumor destruction by the application of laser light, delivered through quartz diffusing laser fibers that can be percutaneously placed within tumors [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/63/35831/abstract/32-34\">",
"       32-34",
"      </a>",
"      ]. This technique can be used to treat lesions that are up to 5 cm in diameter [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/63/35831/abstract/33\">",
"       33",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Transarterial chemoembolization (TACE) is able to deliver chemotherapy directly to the tumor while blocking blood flow to the liver because the majority of the blood supply to liver tumors is from the hepatic artery rather than the portal vein. Experience with these techniques in patients with breast cancer is limited [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/63/35831/abstract/35-38\">",
"       35-38",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Stereotactic Body Radiation Therapy (SBRT or fractionated radiosurgery) is a technique that delivers external beam radiation to the tumor using high-dose, precisely focused beams of radiation. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/21/43350?source=see_link\">",
"       \"Stereotactic body radiation therapy: Rationale and clinical experience\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Brain metastases",
"    </span>",
"    &nbsp;&mdash;&nbsp;As patients with metastatic breast cancer live longer, the incidence of brain metastases appears to be increasing. The risk factors, prognosis, and management of brain metastases in breast cancer are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/0/19464?source=see_link\">",
"     \"Management of brain metastases in breast cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Bone metastases",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bone is the most common site of metastatic involvement in breast cancer and can be associated with significant morbidity and mortality. Surgery, RT, and RFA can provide effective pain relief and prevent fracture. Surgery and RT is also used for the palliative treatment of epidural spinal cord or nerve compression. Bisphosphonates and other osteoclast inhibitors have been shown to reduce the morbidity of metastatic bone disease, in particular skeletal-related events (SREs), which include fracture, need for surgery or radiation to bone, spinal cord compression, and hypercalcemia of malignancy.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?7/54/8042?source=see_link\">",
"       \"Osteoclast inhibition in the management of bone metastases from breast cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/8/33924?source=see_link\">",
"       \"Radiation therapy for the management of painful bone metastases\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/21/26970?source=see_link\">",
"       \"Treatment and prognosis of neoplastic epidural spinal cord compression, including cauda equina syndrome\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Bone-confined metastatic breast cancer is usually characterized by an indolent course and good response to systemic therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/63/35831/abstract/39-41\">",
"     39-41",
"    </a>",
"    ]. There is a limited role for resection as a curative option for the majority of bone metastases, except for selected patients with isolated spine or sternal involvement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/63/35831/abstract/42-46\">",
"     42-46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Sternal metastases may remain solitary for a long time, possibly because there is no communication with the paravertebral venous plexus through which cancer cells can spread to other bones [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/63/35831/abstract/45,47\">",
"     45,47",
"    </a>",
"    ]. In other cases, isolated sternal involvement represents locoregional recurrence (ie, direct extension from an internal mammary nodal recurrence) rather than true metastatic disease. Surgical resection of breast cancer confined to the sternum may improve quality of life and prolong survival.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Abdominal and pelvic metastases",
"    </span>",
"    &nbsp;&mdash;&nbsp;Limited data suggest ovarian breast cancer metastases can appear many years following the initial diagnosis of breast cancer and tend to be hormone receptor-positive [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/63/35831/abstract/48-51\">",
"     48-51",
"    </a>",
"    ]. Surgical evaluation of an adnexal mass may be required to discriminate metastatic breast cancer from a primary ovarian cancer. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/1/24601?source=see_link\">",
"     \"Approach to the patient with an adnexal mass\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36513511\">",
"    <span class=\"h1\">",
"     SYSTEMIC THERAPY AFTER LOCAL TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many patients in the studies described above were treated with systemic therapy, whether chemotherapy or endocrine therapy, either prior to or after local therapy. There is limited evidence that systemic therapy combined with local therapy delays relapse and improves survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/63/35831/abstract/3,52,53\">",
"     3,52,53",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?27/11/27827?source=see_link\">",
"       \"Patient information: Treatment of metastatic breast cancer (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Local therapy may offer therapeutic benefit and the potential for long-term survival for highly selected patients with metastatic breast cancer. However, it is not clear from the available evidence if the local therapy is responsible for long-term survival or if these highly selected patients would have done well anyway. Although there is the most evidence in support of surgical resection, alternative approaches, such as radiofrequency ablation and stereotactic body radiation therapy, are gaining popularity.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patient selection is crucial when considering local therapy. The best candidates are those with solitary metastases in a single metastatic site and a long disease-free interval. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Selection of patients'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Perhaps the main indication for resection of a new, isolated pulmonary, hepatic, or abdominopelvic lesion in a patient with a prior history of breast cancer is diagnostic, since some patients may have a new primary malignancy or a change in tumor marker status. (See",
"      <a class=\"local\" href=\"#H36512642\">",
"       'Local treatment of specific sites'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35831/abstract/1\">",
"      Greenberg PA, Hortobagyi GN, Smith TL, et al. Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol 1996; 14:2197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35831/abstract/2\">",
"      Falkson G, Gelman RS, Leone L, Falkson CI. Survival of premenopausal women with metastatic breast cancer. Long-term follow-up of Eastern Cooperative Group and Cancer and Leukemia Group B studies. Cancer 1990; 66:1621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35831/abstract/3\">",
"      Hanrahan EO, Broglio KR, Buzdar AU, et al. Combined-modality treatment for isolated recurrences of breast carcinoma: update on 30 years of experience at the University of Texas M.D. Anderson Cancer Center and assessment of prognostic factors. Cancer 2005; 104:1158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35831/abstract/4\">",
"      Lee CG, McCormick B, Mazumdar M, et al. Infiltrating breast carcinoma in patients age 30 years and younger: long term outcome for life, relapse, and second primary tumors. Int J Radiat Oncol Biol Phys 1992; 23:969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35831/abstract/5\">",
"      Vogel CL, Azevedo S, Hilsenbeck S, et al. Survival after first recurrence of breast cancer. The Miami experience. Cancer 1992; 70:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35831/abstract/6\">",
"      Ly BH, Nguyen NP, Vinh-Hung V, et al. Loco-regional treatment in metastatic breast cancer patients: is there a survival benefit? Breast Cancer Res Treat 2010; 119:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35831/abstract/7\">",
"      Friedel G, Pastorino U, Ginsberg RJ, et al. Results of lung metastasectomy from breast cancer: prognostic criteria on the basis of 467 cases of the International Registry of Lung Metastases. Eur J Cardiothorac Surg 2002; 22:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35831/abstract/8\">",
"      Friedel G, Linder A, Toomes H. The significance of prognostic factors for the resection of pulmonary metastases of breast cancer. Thorac Cardiovasc Surg 1994; 42:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35831/abstract/9\">",
"      Pagani O, Senkus E, Wood W, et al. International guidelines for management of metastatic breast cancer: can metastatic breast cancer be cured? J Natl Cancer Inst 2010; 102:456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35831/abstract/10\">",
"      Fields RC, Jeffe DB, Trinkaus K, et al. Surgical resection of the primary tumor is associated with increased long-term survival in patients with stage IV breast cancer after controlling for site of metastasis. Ann Surg Oncol 2007; 14:3345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35831/abstract/11\">",
"      Pocard M, Pouillart P, Asselain B, et al. [Hepatic resection for breast cancer metastases: results and prognosis (65 cases)]. Ann Chir 2001; 126:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35831/abstract/12\">",
"      Yoshimoto M, Tada T, Saito M, et al. Surgical treatment of hepatic metastases from breast cancer. Breast Cancer Res Treat 2000; 59:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35831/abstract/13\">",
"      Sofocleous CT, Nascimento RG, Gonen M, et al. Radiofrequency ablation in the management of liver metastases from breast cancer. AJR Am J Roentgenol 2007; 189:883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35831/abstract/14\">",
"      Selzner M, Morse MA, Vredenburgh JJ, et al. Liver metastases from breast cancer: long-term survival after curative resection. Surgery 2000; 127:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35831/abstract/15\">",
"      Ludwig C, Stoelben E, Hasse J. Disease-free survival after resection of lung metastases in patients with breast cancer. Eur J Surg Oncol 2003; 29:532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35831/abstract/16\">",
"      Planchard D, Soria JC, Michiels S, et al. Uncertain benefit from surgery in patients with lung metastases from breast carcinoma. Cancer 2004; 100:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35831/abstract/17\">",
"      Raab R, Nussbaum KT, Behrend M, Weimann A. Liver metastases of breast cancer: results of liver resection. Anticancer Res 1998; 18:2231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35831/abstract/18\">",
"      Long-term results of lung metastasectomy: prognostic analyses based on 5206 cases. The International Registry of Lung Metastases. J Thorac Cardiovasc Surg 1997; 113:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35831/abstract/19\">",
"      McDonald ML, Deschamps C, Ilstrup DM, et al. Pulmonary resection for metastatic breast cancer. Ann Thorac Surg 1994; 58:1599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35831/abstract/20\">",
"      Yoshimoto M, Tada K, Nishimura S, et al. Favourable long-term results after surgical removal of lung metastases of breast cancer. Breast Cancer Res Treat 2008; 110:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35831/abstract/21\">",
"      Cahan WG, Castro EB. Significance of a solitary lung shadow in patients with breast cancer. Ann Surg 1975; 181:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35831/abstract/22\">",
"      Casey JJ, Stempel BG, Scanlon EF, Fry WA. The solitary pulmonary nodule in the patient with breast cancer. Surgery 1984; 96:801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35831/abstract/23\">",
"      Hoe AL, Royle GT, Taylor I. Breast liver metastases--incidence, diagnosis and outcome. J R Soc Med 1991; 84:714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35831/abstract/24\">",
"      Atalay G, Biganzoli L, Renard F, et al. Clinical outcome of breast cancer patients with liver metastases alone in the anthracycline-taxane era: a retrospective analysis of two prospective, randomised metastatic breast cancer trials. Eur J Cancer 2003; 39:2439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35831/abstract/25\">",
"      Zinser JW, Hortobagyi GN, Buzdar AU, et al. Clinical course of breast cancer patients with liver metastases. J Clin Oncol 1987; 5:773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35831/abstract/26\">",
"      Chua TC, Saxena A, Liauw W, et al. Hepatic resection for metastatic breast cancer: a systematic review. Eur J Cancer 2011; 47:2282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35831/abstract/27\">",
"      Maksan SM, Lehnert T, Bastert G, Herfarth C. Curative liver resection for metastatic breast cancer. Eur J Surg Oncol 2000; 26:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35831/abstract/28\">",
"      Wood TF, Rose DM, Chung M, et al. Radiofrequency ablation of 231 unresectable hepatic tumors: indications, limitations, and complications. Ann Surg Oncol 2000; 7:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35831/abstract/29\">",
"      de Baere T, Elias D, Dromain C, et al. Radiofrequency ablation of 100 hepatic metastases with a mean follow-up of more than 1 year. AJR Am J Roentgenol 2000; 175:1619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35831/abstract/30\">",
"      Pawlik TM, Izzo F, Cohen DS, et al. Combined resection and radiofrequency ablation for advanced hepatic malignancies: results in 172 patients. Ann Surg Oncol 2003; 10:1059.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35831/abstract/31\">",
"      Livraghi T, Goldberg SN, Solbiati L, et al. Percutaneous radio-frequency ablation of liver metastases from breast cancer: initial experience in 24 patients. Radiology 2001; 220:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35831/abstract/32\">",
"      Izzo F. Other thermal ablation techniques: microwave and interstitial laser ablation of liver tumors. Ann Surg Oncol 2003; 10:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35831/abstract/33\">",
"      Nikfarjam M, Christophi C. Interstitial laser thermotherapy for liver tumours. Br J Surg 2003; 90:1033.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35831/abstract/34\">",
"      Mack MG, Straub R, Eichler K, et al. Breast cancer metastases in liver: laser-induced interstitial thermotherapy--local tumor control rate and survival data. Radiology 2004; 233:400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35831/abstract/35\">",
"      Camacho LH, Kurzrock R, Cheung A, et al. Pilot study of regional, hepatic intra-arterial paclitaxel in patients with breast carcinoma metastatic to the liver. Cancer 2007; 109:2190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35831/abstract/36\">",
"      Ikeda T, Adachi I, Takashima S, et al. A phase I/II study of continuous intra-arterial chemotherapy using an implantable reservoir for the treatment of liver metastases from breast cancer: a Japan Clinical Oncology Group (JCOG) study 9113. JCOG Breast Cancer Study Group. Jpn J Clin Oncol 1999; 29:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35831/abstract/37\">",
"      Arai Y, Sone Y, Inaba Y, et al. Hepatic arterial infusion chemotherapy for liver metastases from breast cancer. Cancer Chemother Pharmacol 1994; 33 Suppl:S142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35831/abstract/38\">",
"      Li XP, Meng ZQ, Guo WJ, Li J. Treatment for liver metastases from breast cancer: results and prognostic factors. World J Gastroenterol 2005; 11:3782.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35831/abstract/39\">",
"      Briasoulis E, Karavasilis V, Kostadima L, et al. Metastatic breast carcinoma confined to bone: portrait of a clinical entity. Cancer 2004; 101:1524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35831/abstract/40\">",
"      Sherry MM, Greco FA, Johnson DH, Hainsworth JD. Metastatic breast cancer confined to the skeletal system. An indolent disease. Am J Med 1986; 81:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35831/abstract/41\">",
"      Coleman RE, Smith P, Rubens RD. Clinical course and prognostic factors following bone recurrence from breast cancer. Br J Cancer 1998; 77:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35831/abstract/42\">",
"      van der Linden YM, Dijkstra SP, Vonk EJ, et al. Prediction of survival in patients with metastases in the spinal column: results based on a randomized trial of radiotherapy. Cancer 2005; 103:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35831/abstract/43\">",
"      D&uuml;rr HR, M&uuml;ller PE, Lenz T, et al. Surgical treatment of bone metastases in patients with breast cancer. Clin Orthop Relat Res 2002; :191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35831/abstract/44\">",
"      Incarbone M, Nava M, Lequaglie C, et al. Sternal resection for primary or secondary tumors. J Thorac Cardiovasc Surg 1997; 114:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35831/abstract/45\">",
"      Noguchi S, Miyauchi K, Nishizawa Y, et al. Results of surgical treatment for sternal metastasis of breast cancer. Cancer 1988; 62:1397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35831/abstract/46\">",
"      Lequaglie C, Massone PB, Giudice G, Conti B. Gold standard for sternectomies and plastic reconstructions after resections for primary or secondary sternal neoplasms. Ann Surg Oncol 2002; 9:472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35831/abstract/47\">",
"      Noble J, Sirohi B, Ashley S, et al. Sternal/para-sternal resection for parasternal local recurrence in breast cancer. Breast 2010; 19:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35831/abstract/48\">",
"      Quan ML, Fey J, Eitan R, et al. Role of laparoscopy in the evaluation of the adnexa in patients with stage IV breast cancer. Gynecol Oncol 2004; 92:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35831/abstract/49\">",
"      Abu-Rustum NR, Aghajanian CA, Venkatraman ES, et al. Metastatic breast carcinoma to the abdomen and pelvis. Gynecol Oncol 1997; 66:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35831/abstract/50\">",
"      Curtin JP, Barakat RR, Hoskins WJ. Ovarian disease in women with breast cancer. Obstet Gynecol 1994; 84:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35831/abstract/51\">",
"      Bigorie V, Morice P, Duvillard P, et al. Ovarian metastases from breast cancer: report of 29 cases. Cancer 2010; 116:799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35831/abstract/52\">",
"      Rivera E, Holmes FA, Buzdar AU, et al. Fluorouracil, doxorubicin, and cyclophosphamide followed by tamoxifen as adjuvant treatment for patients with stage IV breast cancer with no evidence of disease. Breast J 2002; 8:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35831/abstract/53\">",
"      Juan O, Lluch A, de Paz L, et al. Prognostic factors in patients with isolated recurrences of breast cancer (stage IV-NED). Breast Cancer Res Treat 1999; 53:105.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 760 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-220.255.2.102-02C9EFC5AA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_63_35831=[""].join("\n");
var outline_f34_63_35831=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H36512206\">",
"      RATIONALE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      SELECTION OF PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Performance status and comorbidity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Oligometastatic disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36513457\">",
"      Disease-free interval",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Complete resection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H36512642\">",
"      LOCAL TREATMENT OF SPECIFIC SITES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Lung metastases",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Liver metastases",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Brain metastases",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Bone metastases",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Abdominal and pelvic metastases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H36513511\">",
"      SYSTEMIC THERAPY AFTER LOCAL TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/760\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/760|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?9/15/9467\" title=\"table 1\">",
"      ECOG performance scale",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/1/24601?source=related_link\">",
"      Approach to the patient with an adnexal mass",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/21/43352?source=related_link\">",
"      Axillary node metastases with occult primary breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/49/10009?source=related_link\">",
"      Clinical features, diagnosis, and staging of newly diagnosed breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/31/44537?source=related_link\">",
"      Diagnostic evaluation and management of the solitary pulmonary nodule",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/0/19464?source=related_link\">",
"      Management of brain metastases in breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/53/34650?source=related_link\">",
"      Management of locoregional recurrence of breast cancer after breast conserving therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/45/30426?source=related_link\">",
"      Management of locoregional recurrence of breast cancer after mastectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/54/8042?source=related_link\">",
"      Osteoclast inhibition in the management of bone metastases from breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?27/11/27827?source=related_link\">",
"      Patient information: Treatment of metastatic breast cancer (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/2/15400?source=related_link\">",
"      Preoperative evaluation for lung resection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/8/33924?source=related_link\">",
"      Radiation therapy for the management of painful bone metastases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/42/25255?source=related_link\">",
"      Radiofrequency ablation of lung tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/12/4292?source=related_link\">",
"      Role of breast surgery for stage IV breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/47/17143?source=related_link\">",
"      Stereotactic body radiation therapy for primary and metastatic lung tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/21/43350?source=related_link\">",
"      Stereotactic body radiation therapy: Rationale and clinical experience",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/11/7354?source=related_link\">",
"      Systemic treatment for metastatic breast cancer: General principles",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/21/26970?source=related_link\">",
"      Treatment and prognosis of neoplastic epidural spinal cord compression, including cauda equina syndrome",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_63_35832="Treatment of pelvic inflammatory disease";
var content_f34_63_35832=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of pelvic inflammatory disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/63/35832/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/63/35832/contributors\">",
"     Harold C Wiesenfeld, MD, CM",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/63/35832/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/63/35832/contributors\">",
"     Noreen A Hynes, MD, MPH, DTM&amp;H",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/63/35832/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/63/35832/contributors\">",
"     Allyson Bloom, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?34/63/35832/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 24, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pelvic inflammatory disease (PID) refers to acute infection of the upper genital tract structures in women, involving any or all of the uterus, fallopian tubes, and ovaries and may involve the neighboring pelvic organs. Early diagnosis and treatment are believed to be key elements in the prevention of long-term sequelae, such as infertility and ectopic pregnancy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/0/1032?source=see_link\">",
"     \"Clinical features and diagnosis of pelvic inflammatory disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The treatment of PID will be reviewed here. The pathogenesis of risk factors for acquisition of, and sequelae following this disorder are discussed separately. The management of tubo-ovarian abscess is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/45/11992?source=see_link\">",
"     \"Pathogenesis of and risk factors for pelvic inflammatory disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/58/934?source=see_link\">",
"     \"Long-term complications of pelvic inflammatory disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/34/43560?source=see_link\">",
"     \"Management and complications of tuboovarian abscess\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CANDIDATES FOR TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinicians should maintain a low threshold of suspicion for the diagnosis of PID since long-term complications are more common if treatment is delayed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/63/35832/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Acute PID should be considered in sexually active young women with the combination of lower abdominal pain with pelvic tenderness (cervical motion tenderness, uterine tenderness, or adnexal tenderness) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/63/35832/abstract/1\">",
"     1",
"    </a>",
"    ]. Occasionally, acute PID may be encountered in women without recent sexual activity. Information regarding major and minor diagnostic criteria for PID is found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/0/1032?source=see_link\">",
"     \"Clinical features and diagnosis of pelvic inflammatory disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PATHOGENS OF CONCERN",
"    </span>",
"    &nbsp;&mdash;&nbsp;PID is primarily a disease of sexually active women. The two most important sexually transmitted organisms associated with acute PID, Chlamydia trachomatis and Neisseria gonorrhoeae, should be targeted for treatment; negative endocervical screening for either of these pathogens does not rule out upper tract infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/63/35832/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    PID is a polymicrobial infection, which generally requires broad coverage, particularly among those with severe disease requiring hospitalization. Acute PID is an ascending infection caused by cervical microorganisms (including Chlamydia trachomatis and Neisseria gonorrhoeae), as well as the vaginal microflora, including anaerobic organisms, enteric gram-negative rods, streptococci, genital mycoplasmas, and Gardnerella vaginalis, which is associated bacterial vaginosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/63/35832/abstract/2\">",
"     2",
"    </a>",
"    ]. Bacterial vaginosis results in complex alterations of the normal vaginal flora, which may alter host defense mechanisms in the cervicovaginal environment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/63/35832/abstract/2-5\">",
"     2-5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In studies utilizing specialized techniques, anaerobic organisms were frequently recovered from the upper genital tract in women with acute PID. &nbsp;However, the importance of effective treatment of anaerobic organisms in women with acute PID is somewhat controversial and is currently under study (Clinical Trials.gov identifier NCT01160640) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/63/35832/abstract/5\">",
"     5",
"    </a>",
"    ]. Rarely, actinomycetes may be isolated in the patient with an intrauterine device (IUD).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1024892\">",
"    <span class=\"h1\">",
"     AVAILABLE ANTIMICROBIAL AGENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple antibacterial agents with activity against the wide variety of implicated pathogens have been studied, including medications within the beta-lactam, fluoroquinolone, aminoglycoside, lincosamide and macrolide classes of drugs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/63/35832/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]. Meta-analyses of selected trials have demonstrated overall clinical and microbiological cure rates of greater than 90 percent for most regimens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/63/35832/abstract/6,7\">",
"     6,7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The vast majority of these studies have included dual therapy arms for coverage of N. gonorrhoeae, C. trachomatis, and the wide variety of microbes associated with PID;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    has been the agent of choice for coverage of C. trachomatis in most of these studies, although",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    also has activity against this pathogen. The combination of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/10/36000?source=see_link\">",
"     gentamicin",
"    </a>",
"    has moderate in vitro activity against N. gonorrhoeae and C. trachomatis, while a second generation cephalosporin (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/53/11094?source=see_link\">",
"     cefoxitin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/55/17269?source=see_link\">",
"     cefotetan",
"    </a>",
"    ) plus doxycycline have excellent in vitro activity against both pathogens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/63/35832/abstract/3,9\">",
"     3,9",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/8/1160?source=see_link\">",
"     Ampicillin-sulbactam",
"    </a>",
"    is a beta-lactam agent with broad spectrum activity, although there are scant data on its use for the treatment of PID [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/63/35832/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Fluoroquinolones are no longer recommended in the United States for the treatment of gonorrhea or associated conditions, such as PID, due to increasing rates of resistance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/63/35832/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H1025375\">",
"     'Gonococcal drug resistance'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H412704\">",
"    <span class=\"h1\">",
"     CLINICAL TRIAL DATA",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H412907\">",
"    <span class=\"h2\">",
"     Defining treatment response",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment response is based on both short- and long-term outcomes. Clinical cure is defined as &ldquo;significant&rdquo; or &ldquo;complete improvement&rdquo; in the signs",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    symptoms of PID. Microbiologic cure is defined as eradication of N. gonorrhoeae or C. trachomatis, if present at baseline.",
"   </p>",
"   <p>",
"    Long-term sequelae of PID include infertility, ectopic pregnancy, and chronic pelvic pain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H412960\">",
"    <span class=\"h2\">",
"     Limitations of current data sets",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are multiple limitations of the clinical trials of PID treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1224669\">",
"    <span class=\"h3\">",
"     Clinical efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some studies have not used objective criteria to diagnose PID, raising concerns as to the whether the appropriate patient population was included [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/63/35832/abstract/6\">",
"     6",
"    </a>",
"    ]. In addition, others have evaluated subjective improvement in pain scores without blinding of investigators [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/63/35832/abstract/6\">",
"     6",
"    </a>",
"    ]. Few randomized controlled trials have long-term data on reproductive outcomes, such as risk of ectopic pregnancy following treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1224676\">",
"    <span class=\"h3\">",
"     Microbiologic efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although several studies have demonstrated the presence of anaerobes at initial presentation, there are scant data on their persistence or eradication after therapy. In fact, excellent clinical cure rates among women with mild to moderate PID have been documented for several regimens with modest anaerobic coverage (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/63/35832/abstract/5,11\">",
"     5,11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Assessment of efficacy is also hampered by diagnostic methods that do not distinguish between relapse versus reinfection. The Pelvic Inflammation Disease Evaluation Clinical Health trial (ie, PEACH trial), which carefully assessed patients for N. gonorrhoeae and C. trachomatis infections, demonstrated that 40 percent of the women had evidence of single or dual infections at baseline; by 30 days after therapeutic invention, approximately 3 percent still had evidence of either infection, representing either reinfection or relapse.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H412876\">",
"    <span class=\"h2\">",
"     Management of mild or moderate PID",
"    </span>",
"    &nbsp;&mdash;&nbsp;There has been a persistent trend toward outpatient treatment of PID with only 10 to 25 percent of women now being hospitalized [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/63/35832/abstract/12\">",
"     12",
"    </a>",
"    ]. Clinical trial data support such an approach in patients with mild or moderate PID. The Pelvic Inflammation Disease Evaluation Clinical Health trial (ie, PEACH trial) randomly assigned 831 patients with mild or moderate PID to either [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/63/35832/abstract/13\">",
"     13",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Inpatient therapy with intravenous",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/53/11094?source=see_link\">",
"       cefoxitin",
"      </a>",
"      (2 grams every 6 hours) plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"       doxycycline",
"      </a>",
"      (100 mg twice daily for 14 days)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    OR",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Outpatient therapy with a single intramuscular dose of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/53/11094?source=see_link\">",
"       cefoxitin",
"      </a>",
"      (2 grams) plus a single dose of oral",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/18/37157?source=see_link\">",
"       probenecid",
"      </a>",
"      (1 gram) plus oral",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"       doxycycline",
"      </a>",
"      (100 mg twice daily for 14 days) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/63/35832/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Eligible women had a history of lower abdominal pain, uterine or adnexal tenderness on examination, and",
"    <span class=\"nowrap\">",
"     leukorrhea/mucopurulent",
"    </span>",
"    cervicitis or documented untreated gonococcal or chlamydial infection. Patients underwent a standardized interview, and cervical swabs were obtained for N. gonorrhoeae and C. trachomatis for polymerase chain reaction (PCR) testing. Vaginal specimens were Gram stained and examined for evidence of bacterial vaginosis by a reference laboratory. Endometrial biopsies were scored for evidence of endometritis by two reference pathologists. Long-term follow-up was conducted through periodic phone calls. Intravenous therapy continued for a minimum of 48 hours; upon clinical improvement, the patient was switched to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    for a 14-day course.",
"   </p>",
"   <p>",
"    This clinical trial showed that short-term clinical and microbiologic outcomes and long-term reproductive outcomes (eg, ectopic pregnancy, chronic pelvic pain) were similar between arms. Intravenous administration of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    was associated with high rates of phlebitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1024815\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR HOSPITALIZATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recommended indications for hospitalization and parenteral antibiotics include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/63/35832/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Pregnancy",
"     </li>",
"     <li>",
"      Lack of response or tolerance to oral medications",
"     </li>",
"     <li>",
"      Nonadherence to therapy",
"     </li>",
"     <li>",
"      Inability to take oral medications due to nausea and vomiting",
"     </li>",
"     <li>",
"      Severe clinical illness (high fever, nausea, vomiting, severe abdominal pain)",
"     </li>",
"     <li>",
"      Complicated PID with pelvic abscess (including tuboovarian abscess)",
"     </li>",
"     <li>",
"      Possible need for surgical intervention or diagnostic exploration for alternative etiology (eg, appendicitis)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There are no clinical data to suggest that older age or HIV status should be considered criteria for hospitalization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/63/35832/abstract/3,14\">",
"     3,14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     RECOMMENDED REGIMENS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H413108\">",
"    <span class=\"h2\">",
"     General approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;The therapeutic regimens for PID, discussed below, provide broad empiric coverage for the wide array of implicated pathogens, although the optimal treatment regimen remains undefined [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/63/35832/abstract/13\">",
"     13",
"    </a>",
"    ]. Antibiotics selected should have activity against Neisseria gonorrhoeae and Chlamydia trachomatis, as both play a significant role in PID. As noted above, meta-analyses have demonstrated that a variety of antibiotics from multiple classes are all associated with clinical and microbiologic cure rates of greater than 90 percent. Cost, convenience of administration, safety, formulary availability and allergy history are all assessed in making antimicrobial selections. The choice of antimicrobial therapy is also guided by whether the patient will be treated as an inpatient or outpatient.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1025375\">",
"    <span class=\"h2\">",
"     Gonococcal drug resistance",
"    </span>",
"    &nbsp;&mdash;&nbsp;As of 2007, the CDC guidelines state that fluoroquinolones are no longer recommended as therapy for PID if N. gonorrhoeae is a proven or suspect pathogen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/63/35832/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1025421\">",
"    <span class=\"h2\">",
"     Role for anaerobic coverage",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no consensus on the degree of anaerobic coverage that is needed for PID or whether anaerobes need to be targeted at all [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/63/35832/abstract/3,5\">",
"     3,5",
"    </a>",
"    ]. Anaerobic bacteria are frequently recovered from patients with acute PID; however, there are no studies to demonstrate that inclusion of anaerobic coverage is superior to antibiotic regimens with minimal coverage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/63/35832/abstract/3\">",
"     3",
"    </a>",
"    ]. Furthermore, experts are concerned that the additional gastrointestinal side effects seen with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    therapy will lead to nonadherence and inadequately treated PID.",
"   </p>",
"   <p>",
"    Some experts have suggested that anaerobes should be treated empirically while others suggest inclusion of anaerobic coverage among select groups of patients, such as those with severe infection requiring hospitalization and tubo-ovarian abscess [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/63/35832/abstract/5\">",
"     5",
"    </a>",
"    ]. The inpatient regimens noted below have excellent anaerobic coverage while the outpatient regimens have only modest coverage. The addition of antibiotics with anaerobic activity (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    ) may be considered among outpatients with:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      History of gynecological instrumentation within the preceding two to three weeks (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/34/43560?source=see_link\">",
"       \"Management and complications of tuboovarian abscess\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1025616\">",
"    <span class=\"h2\">",
"     Inpatient therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with severe PID should be hospitalized and treated with parenteral therapy. Indications for hospitalization are discussed above. (See",
"    <a class=\"local\" href=\"#H1024815\">",
"     'Indications for hospitalization'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1025583\">",
"    <span class=\"h3\">",
"     First-line therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with severe PID, the CDC recommends either of the following parenteral regimens, which result in clinical cure of acute disease in &gt;90 percent of PID cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/63/35832/abstract/1,15-17\">",
"     1,15-17",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/53/11094?source=see_link\">",
"       Cefoxitin",
"      </a>",
"      (2 g intravenously every 6 hours) or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/55/17269?source=see_link\">",
"       cefotetan",
"      </a>",
"      (2 g IV every 12 hours) plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"       doxycycline",
"      </a>",
"      (100 mg orally every 12 hours).",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/21/33104?source=see_link\">",
"       Clindamycin",
"      </a>",
"      (900 mg intravenously every 8 hours) plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/10/36000?source=see_link\">",
"       gentamicin",
"      </a>",
"      loading dose (2",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      of body weight) followed by a maintenance dose (1.5",
"      <span class=\"nowrap\">",
"       mg/kg)",
"      </span>",
"      every 8 hours. Single daily intravenous dosing of gentamicin may be substituted for three times daily dosing [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/63/35832/abstract/1\">",
"       1",
"      </a>",
"      ]. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These inpatient regimens provide broad coverage, including streptococci, gram-negative enteric bacilli (Escherichia coli, Klebsiella spp, and Proteus spp), and anaerobic organisms (ie, bacterial vaginosis-associated flora) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/63/35832/abstract/7,18-20\">",
"     7,18-20",
"    </a>",
"    ]. We prefer a second generation cephalosporin plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    for inpatients with PID due to its overall tolerability.",
"   </p>",
"   <p>",
"    Antiemetic and antipyretic medications should be offered to those patients who are symptomatic. Transitioning from parenteral to oral therapy can usually be started after 24 hours of sustained clinical improvement, such as resolution of fever, nausea, vomiting, and severe abdominal pain, if present [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/63/35832/abstract/21\">",
"     21",
"    </a>",
"    ]. Patients should complete a 14-day course of treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    (100 mg twice daily). Oral administration of doxycycline is generally preferred, as soon as vomiting subsides, because of the pain associated with intravenous drug administration. Importantly, the bioavailability of the oral preparation of doxycycline is equivalent to parenteral administration.",
"   </p>",
"   <p>",
"    Patients with a pelvic abscess should also receive oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    450 mg every 6 hours or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    500 mg every 8 hours for a total of 14 days in addition to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    . Management of the patient with complicated PID with tubo-ovarian abscess is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/34/43560?source=see_link&amp;anchor=H26297647#H26297647\">",
"     \"Management and complications of tuboovarian abscess\", section on 'Management'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2577820\">",
"    <span class=\"h3\">",
"     Alternative regimens",
"    </span>",
"    &nbsp;&mdash;&nbsp;Limited data are available on the following regimens, which are considered &ldquo;alternative&rdquo; by the CDC:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?1/8/1160?source=see_link\">",
"       Ampicillin-sulbactam",
"      </a>",
"      (3 g intravenous every 6 hours) plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"       doxycycline",
"      </a>",
"      (100 mg twice daily) led to a similar rate of clinical cure as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/53/11094?source=see_link\">",
"       cefoxitin",
"      </a>",
"      (2 g every 6 hours) plus doxycycline (100 mg twice daily) among women hospitalized with PID (86 versus 89 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/63/35832/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      One small trial randomly assigned patients with mild or moderate PID to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/43/33456?source=see_link\">",
"       azithromycin",
"      </a>",
"      monotherapy, azithromycin plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/38/20065?source=see_link\">",
"       metronidazole",
"      </a>",
"      , or a combination regimen including a beta-lactam [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/63/35832/abstract/22\">",
"       22",
"      </a>",
"      ]. Clinical and microbiological cure rates were greater than 95 percent in all arms.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H413397\">",
"    <span class=\"h2\">",
"     Outpatient therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with mild or moderate PID are suitable candidates for oral therapy since clinical outcomes are equivalent with parenteral or oral therapy. (See",
"    <a class=\"local\" href=\"#H412876\">",
"     'Management of mild or moderate PID'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2577827\">",
"    <span class=\"h3\">",
"     First-line regimens",
"    </span>",
"    &nbsp;&mdash;&nbsp;The CDC recommends any of the following oral regimens, with or without",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    (500 mg twice a day for 14 days) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/63/35832/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/17/10521?source=see_link\">",
"       Ceftriaxone",
"      </a>",
"      (250 mg intramuscularly in a single dose) plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"       doxycycline",
"      </a>",
"      (100 mg orally twice a day for 14 days)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/53/11094?source=see_link\">",
"       Cefoxitin",
"      </a>",
"      (2 g intramuscularly in a single dose) concurrently with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/18/37157?source=see_link\">",
"       probenecid",
"      </a>",
"      (1 g orally in a single dose) plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"       doxycycline",
"      </a>",
"      (100 mg orally twice a day for 14 days)",
"     </li>",
"     <li>",
"      Other parenteral third-generation cephalosporins, such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/57/35735?source=see_link\">",
"       cefotaxime",
"      </a>",
"      (1 gram intramuscularly in a single dose) or ceftizoxime (1 gram intramuscularly in a single dose) plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"       doxycycline",
"      </a>",
"      (100 mg orally twice a day for 14 days)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Of the cephalosporins listed,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    has the overall best activity against gonococcal infection. We prefer ceftriaxone plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    in patients with mild to moderate PID.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/38/20065?source=see_link\">",
"     Metronidazole",
"    </a>",
"    should be added for patients with Trichomonas vaginalis or in those women with a recent history of uterine instrumentation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Alternative agents",
"    </span>",
"   </p>",
"   <p>",
"    The long half-life of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    , its concentration intracellularly, and its activity against Chlamydia offers the potential for an easier dosing schedule than twice-daily",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    . Small clinical trials suggest clinical efficacy although data on microbiological cures are not available:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A double-blind randomized controlled trial compared the efficacy of a single intramuscular injection of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/17/10521?source=see_link\">",
"       ceftriaxone",
"      </a>",
"      followed by either",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"       doxycycline",
"      </a>",
"      (100 mg twice daily for two weeks) or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/43/33456?source=see_link\">",
"       azithromycin",
"      </a>",
"      (1 gram once per week for two weeks) in 120 women with mild PID [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/63/35832/abstract/23\">",
"       23",
"      </a>",
"      ]. The azithromycin and doxycycline arms were found to be equivalent in clinical cure rates. The study limitations include the subjective nature of the measured outcome, limited microbiologic data and the small sample size.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H413492\">",
"    <span class=\"h1\">",
"     TREATMENT OF THE PENICILLIN-ALLERGIC PATIENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment considerations must also take into consideration any history of drug allergy and the risk for gonococcal infection. Penicillin-allergic patients who have tolerated cephalosporins may be treated with a cephalosporin-based regimen.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H414047\">",
"    <span class=\"h2\">",
"     Patients at risk for gonorrhea",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with PID who require hospitalization can be treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/10/36000?source=see_link\">",
"     gentamicin",
"    </a>",
"    , as outlined above. (See",
"    <a class=\"local\" href=\"#H1025616\">",
"     'Inpatient therapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    However, therapeutic options for outpatient management of the penicillin allergic patient at risk for gonorrhea are limited, particularly among those with a history of severe penicillin allergy. In patients with mild or moderate PID, it is important to obtain a complete history regarding the underlying penicillin allergy so a therapeutic regimen may be constructed, as discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1225117\">",
"    <span class=\"h3\">",
"     History of mild allergy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A patient with a mild past reaction to a penicillin and who never reacted to a cephalosporin (or never received one) may be a candidate for treatment with intramuscular",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    A history of a maculopapular or morbilliform rash, without signs of IgE-mediated allergy (urticaria, angioedema, respiratory symptoms, hypotension) or desquamation, is associated with very low risk for a serious allergic reaction to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    . Cross-reactivity between penicillins and third-generation cephalosporins is believed to be uncommon. For such patients, an initial test dose of ceftriaxone (one-tenth of the full dose, intramuscularly) can be administered with patient observation for two hours. If no reaction develops, the remainder of the dose can be given with continued observation for another hour; the patient should be discharged with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    (100 mg twice daily) for 14 days. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/19/15672?source=see_link\">",
"     \"Penicillin-allergic patients: Use of cephalosporins, carbapenems, and monobactams\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1225153\">",
"    <span class=\"h3\">",
"     History of severe allergy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with severe or life-threatening penicillin allergies are not candidates for cephalosporin therapy; options for outpatient therapy are limited.",
"   </p>",
"   <p>",
"    We suggest the following possible options:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hospitalize the patient and initiate treatment with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/21/33104?source=see_link\">",
"       clindamycin",
"      </a>",
"      (900 mg intravenously every 8 hours) plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/10/36000?source=see_link\">",
"       gentamicin",
"      </a>",
"      loading dose (2",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      of body weight) followed by a maintenance dose (1.5",
"      <span class=\"nowrap\">",
"       mg/kg)",
"      </span>",
"      every 8 hours. Single daily intravenous dosing of gentamicin may be substituted [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/63/35832/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    OR",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Administer a quinolone-based regimen, eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/46/33504?source=see_link\">",
"       levofloxacin",
"      </a>",
"      (500 mg orally once daily for 14 days) AND a single dose of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/43/33456?source=see_link\">",
"       azithromycin",
"      </a>",
"      (2 grams orally). This dosage of azithromycin is also used for penicillin allergic patients with uncomplicated gonococcal infection; however, this high dose of azithromycin is associated with increased rates of gastrointestinal disturbance. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?19/3/19514?source=see_link&amp;anchor=H195635379#H195635379\">",
"       \"Treatment of uncomplicated gonococcal infections\", section on 'Azithromycin monotherapy'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?19/3/19514?source=see_link&amp;anchor=H279612#H279612\">",
"       \"Treatment of uncomplicated gonococcal infections\", section on 'Penicillin allergic patients'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Following 24 hours of clinical improvement, treatment may be changed to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    (100 mg orally every 12 hours) to complete 14 days of treatment. In the patient with uncomplicated PID, another fluoroquinolone alternative to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/46/33504?source=see_link\">",
"     levofloxacin",
"    </a>",
"    is",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/51/33584?source=see_link\">",
"     moxifloxacin",
"    </a>",
"    (400 mg) once daily for 14 days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/63/35832/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H414054\">",
"    <span class=\"h2\">",
"     Patients at low risk of gonorrhea",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, fluoroquinolones are not recommended for the treatment of PID because of the risk of gonococcal drug resistance.",
"   </p>",
"   <p>",
"    However, fluoroquinolones, with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    , may be considered for PID therapy in circumstances where N. gonorrhoeae is not likely to be a causative agent (eg, the post-menopausal woman who develops PID following uterine instrumentation) or when the prevalence of fluoroquinolone-resistant N. gonorrhoeae is &lt;5 percent in the locality where the infection was acquired [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/63/35832/abstract/10\">",
"     10",
"    </a>",
"    ]; resistance data can be obtained from the local department of public health. Fluoroquinolone resistance is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/3/19514?source=see_link&amp;anchor=H7889004#H7889004\">",
"     \"Treatment of uncomplicated gonococcal infections\", section on 'Antibiotic resistance'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Thus, an alternate treatment regimen in these clinical scenarios may include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/46/33504?source=see_link\">",
"       Levofloxacin",
"      </a>",
"      (500 mg orally once daily) or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/60/35776?source=see_link\">",
"       ofloxacin",
"      </a>",
"      (400 mg orally twice daily) with or without",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/38/20065?source=see_link\">",
"       metronidazole",
"      </a>",
"      (500 mg orally twice a day); monotherapy with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/51/33584?source=see_link\">",
"       moxifloxacin",
"      </a>",
"      (400 mg once daily), which has good anaerobic coverage, is another option. All regimens are given for 14 days.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Prior to quinolone treatment, cervical specimens should be collected for culture for Neisseria gonorrhoeae so that the initial treatment regimen can be altered if fluoroquinolone-resistant N. gonorrhoeae are identified. Nucleic acid amplification testing cannot determine antimicrobial susceptibility. The laboratory should be notified to perform susceptibility testing on N. gonorrhoeae isolates.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H413500\">",
"    <span class=\"h1\">",
"     HIV-INFECTED PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;HIV-infected women appear to respond to therapy for PID as well as uninfected women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/63/35832/abstract/14\">",
"     14",
"    </a>",
"    ]. Therefore, recommended antibiotic regimens for HIV-infected women with acute PID are similar to those for HIV-uninfected women.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     DURATION OF THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal duration of therapy is unknown. Most studies have used 14 days of therapy and this duration has been maintained in the 2010 STD recommendations from the CDC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/63/35832/abstract/1,10\">",
"     1,10",
"    </a>",
"    ]. Shorter courses of therapy have not been explored, mainly related to concerns regarding eradication of C. trachomatis in the setting of upper tract disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/63/35832/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     PATIENT RELATED ISSUES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patient monitoring and counseling are important components of overall management. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H413824\">",
"    <span class=\"h2\">",
"     Patient monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;If outpatient therapy is selected, it is important to see the patient within 48 to 72 hours to be certain that clinical improvement has occurred (eg, reduction in abdominal tenderness and reduction in cervical motion tenderness) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/63/35832/abstract/24\">",
"     24",
"    </a>",
"    ]. If no clinical improvement has occurred within 72 hours, hospitalization, parenteral therapy, and further diagnostic evaluation is recommended [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/63/35832/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Medication adherence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Compliance with a long course of oral antibiotics can be problematic [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/63/35832/abstract/25\">",
"     25",
"    </a>",
"    ]. Patients should be educated about the importance of medication adherence and clinical outcomes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Counseling and screening",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinicians should counsel patients regarding the route of acquisition for sexually transmitted infections, the concomitant need for partner treatment, and future safe sex practices. All patients diagnosed with acute PID should be offered HIV testing. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/55/20345?source=see_link\">",
"     \"Diagnostic assays for HIV infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other important components of the evaluation include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hepatitis B surface antigen and surface antibody testing with HBV vaccination for patients who have no evidence of prior infection or immunization",
"     </li>",
"     <li>",
"      Serologic testing for syphilis (eg, RPR)",
"     </li>",
"     <li>",
"      Patients who are 9 through 26 years of age should be offered immunization against human papillomavirus infection, if they have never been vaccinated in the past. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?19/17/19738?source=see_link\">",
"       \"Recommendations for the use of human papillomavirus vaccines\"",
"      </a>",
"      .) &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients diagnosed with acute PID should undergo counseling for safe sex practices. Drug abuse counseling should be offered to appropriate patients. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Sex partners",
"    </span>",
"    &nbsp;&mdash;&nbsp;Male sex partners of women with PID should be examined and treated if they had sexual contact with the patient during the previous 60 days prior to the patient's onset of symptoms, regardless of the woman&rsquo;s sexually transmitted infection test results. Evaluation and treatment of the sex partner is essential to decrease the risk of reinfection. Regimens should include antibiotics with activity against Neisseria gonorrhoeae and Chlamydia trachomatis, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    (250 mg) intramuscularly plus either",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    (1 gram) orally as a single dose or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    (100 mg) orally twice daily for seven days.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?26/14/26850?source=see_link\">",
"       \"Patient information: Pelvic inflammatory disease (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pelvic inflammatory disease (PID) refers to acute infection of the upper genital tract structures in women, involving any or all of the uterus, oviducts,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      ovaries. Up to 10 percent of women with untreated gonorrhea and 20 percent of women with untreated chlamydia infection may go on to develop PID. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Acute PID is caused by cervical microorganisms (including Chlamydia trachomatis and Neisseria gonorrhoeae) as well as the vaginal microflora, including enteric gram-negative rods, streptococci, genital mycoplasmas, and Gardnerella vaginalis. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Pathogens of concern'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Multiple broad-spectrum antibacterial agents have been studied for the treatment of PID, including beta-lactams, fluoroquinolones, aminoglycosides, lincosamides and macrolides. Meta-analyses of selected trials have demonstrated overall clinical and microbiological cure rates of greater than 90 percent for most regimens. Cost, convenience of administration, safety, allergy history, and drug resistance patterns are all assessed in making antimicrobial selections. (See",
"      <a class=\"local\" href=\"#H1024892\">",
"       'Available antimicrobial agents'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Anaerobic coverage is warranted in patients with a history of recent endometrial instrumentation and women with severe or complicated PID (eg, pelvic abscess). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Pathogens of concern'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Due to the rising levels of fluoroquinolone resistance among Neisseria gonorrhoeae isolates, the use of fluoroquinolones is no longer recommended. Cephalosporins still maintain excellent activity against Neisseria gonorrhoeae, although reports of decreasing susceptibility have been reported. (See",
"      <a class=\"local\" href=\"#H1024892\">",
"       'Available antimicrobial agents'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Indications for hospitalization include: pregnancy, nausea and vomiting, severe clinical illness (fevers, chills, severe abdominal pain), suspected pelvic abscess, or a possible alternative diagnosis (eg, appendicitis). (See",
"      <a class=\"local\" href=\"#H1024815\">",
"       'Indications for hospitalization'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment of pelvic inflammatory disease requires broad antimicrobial coverage against the likely pathogens, including Neisseria gonorrhoeae, Chlamydia trachomatis, and the gram-negative and gram-positive organisms that comprise the cervical and vaginal flora. Additional anaerobic coverage may be important among patients with severe or complicated PID. There are multiple potential antibiotic regimens that are suitable for such broad spectrum coverage with proven efficacy in the treatment of PID.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For inpatient management of severe or complicated PID, we suggest use of a second generation cephalosporin (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/53/11094?source=see_link\">",
"       cefoxitin",
"      </a>",
"      2 g intravenously every 6 hours or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/55/17269?source=see_link\">",
"       cefotetan",
"      </a>",
"      2 g IV every 12 hours) combined with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"       doxycycline",
"      </a>",
"      (100 mg orally every 12 hours) (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Another option is",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/21/33104?source=see_link\">",
"       clindamycin",
"      </a>",
"      (900 mg intravenously every eight hours) plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/10/36000?source=see_link\">",
"       gentamicin",
"      </a>",
"      (2",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      loading dose followed by a 1.5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      maintenance dose every eight hours). Single daily intravenous dosing of gentamicin may be substituted for three times daily dosing. (See",
"      <a class=\"local\" href=\"#H1025616\">",
"       'Inpatient therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Transitioning from parenteral to oral therapy (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"       doxycycline",
"      </a>",
"      100 mg twice daily alone) can usually be started after 24 hours of sustained clinical improvement. (See",
"      <a class=\"local\" href=\"#H1025616\">",
"       'Inpatient therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For outpatient therapy of mild or moderate PID, we suggest",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/17/10521?source=see_link\">",
"       ceftriaxone",
"      </a>",
"      (250 mg intramuscularly in a single dose) plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"       doxycycline",
"      </a>",
"      (100 mg orally twice a day for 14 days) (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). We suggest the addition of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/38/20065?source=see_link\">",
"       metronidazole",
"      </a>",
"      (500 mg orally twice a day for 14 days) for those with a history of gynecological instrumentation in the preceding two to three weeks (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H413397\">",
"       'Outpatient therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Management of the penicillin allergic patient will depend on the nature of the penicillin allergy and the risk of gonococcal infection. (See",
"      <a class=\"local\" href=\"#H413492\">",
"       'Treatment of the penicillin-allergic patient'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The optimal duration of therapy is unknown, although most authorities favor 14 days of treatment. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Duration of therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients receiving outpatient therapy should be carefully evaluated for clinical improvement within 72 hours. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Patient related issues'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Male sex partners of women with PID should be examined and treated if they had sexual contact with the patient during the previous 60 days prior to the patient's onset of symptoms to decrease the risk of reinfection. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Sex partners'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     file://www.cdc.gov/std/treatment/2010/default.htm (Accessed on January 03, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35832/abstract/2\">",
"      Soper DE. Pelvic inflammatory disease. Obstet Gynecol 2010; 116:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35832/abstract/3\">",
"      Walker CK, Wiesenfeld HC. Antibiotic therapy for acute pelvic inflammatory disease: the 2006 Centers for Disease Control and Prevention sexually transmitted diseases treatment guidelines. Clin Infect Dis 2007; 44 Suppl 3:S111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35832/abstract/4\">",
"      Short VL, Totten PA, Ness RB, et al. Clinical presentation of Mycoplasma genitalium Infection versus Neisseria gonorrhoeae infection among women with pelvic inflammatory disease. Clin Infect Dis 2009; 48:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35832/abstract/5\">",
"      Walker CK, Workowski KA, Washington AE, et al. Anaerobes in pelvic inflammatory disease: implications for the Centers for Disease Control and Prevention's guidelines for treatment of sexually transmitted diseases. Clin Infect Dis 1999; 28 Suppl 1:S29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35832/abstract/6\">",
"      Walker CK, Kahn JG, Washington AE, et al. Pelvic inflammatory disease: metaanalysis of antimicrobial regimen efficacy. J Infect Dis 1993; 168:969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35832/abstract/7\">",
"      Dodson MG. Antibiotic regimens for treating acute pelvic inflammatory disease. An evaluation. J Reprod Med 1994; 39:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35832/abstract/8\">",
"      Judlin P, Liao Q, Liu Z, et al. Efficacy and safety of moxifloxacin in uncomplicated pelvic inflammatory disease: the MONALISA study. BJOG 2010; 117:1475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35832/abstract/9\">",
"      Hemsell DL, Little BB, Faro S, et al. Comparison of three regimens recommended by the Centers for Disease Control and Prevention for the treatment of women hospitalized with acute pelvic inflammatory disease. Clin Infect Dis 1994; 19:720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35832/abstract/10\">",
"      Centers for Disease Control and Prevention (CDC). Update to CDC's sexually transmitted diseases treatment guidelines, 2006: fluoroquinolones no longer recommended for treatment of gonococcal infections. MMWR Morb Mortal Wkly Rep 2007; 56:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35832/abstract/11\">",
"      Arredondo JL, Diaz V, Gaitan H, et al. Oral clindamycin and ciprofloxacin versus intramuscular ceftriaxone and oral doxycycline in the treatment of mild-to-moderate pelvic inflammatory disease in outpatients. Clin Infect Dis 1997; 24:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35832/abstract/12\">",
"      Rein DB, Kassler WJ, Irwin KL, Rabiee L. Direct medical cost of pelvic inflammatory disease and its sequelae: decreasing, but still substantial. Obstet Gynecol 2000; 95:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35832/abstract/13\">",
"      Ness RB, Soper DE, Holley RL, et al. Effectiveness of inpatient and outpatient treatment strategies for women with pelvic inflammatory disease: results from the Pelvic Inflammatory Disease Evaluation and Clinical Health (PEACH) Randomized Trial. Am J Obstet Gynecol 2002; 186:929.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35832/abstract/14\">",
"      Irwin KL, Moorman AC, O'Sullivan MJ, et al. Influence of human immunodeficiency virus infection on pelvic inflammatory disease. Obstet Gynecol 2000; 95:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35832/abstract/15\">",
"      Drugs for sexually transmitted infections. Treat Guidel Med Lett 2004; 2:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35832/abstract/16\">",
"      McGregor JA, Crombleholme WR, Newton E, et al. Randomized comparison of ampicillin-sulbactam to cefoxitin and doxycycline or clindamycin and gentamicin in the treatment of pelvic inflammatory disease or endometritis. Obstet Gynecol 1994; 83:998.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35832/abstract/17\">",
"      Comparative evaluation of clindamycin/gentamicin and cefoxitin/doxycycline for treatment of pelvic inflammatory disease: a multi-center trial. The European Study Group. Acta Obstet Gynecol Scand 1992; 71:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35832/abstract/18\">",
"      Landers DV, Wolner-Hanssen P, Paavonen J, et al. Combination antimicrobial therapy in the treatment of acute pelvic inflammatory disease. Am J Obstet Gynecol 1991; 164:849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35832/abstract/19\">",
"      Wasserheit JN, Bell TA, Kiviat NB, et al. Microbial causes of proven pelvic inflammatory disease and efficacy of clindamycin and tobramycin. Ann Intern Med 1986; 104:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35832/abstract/20\">",
"      Brunham RC, Binns B, Guijon F, et al. Etiology and outcome of acute pelvic inflammatory disease. J Infect Dis 1988; 158:510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35832/abstract/21\">",
"      Livengood CH 3rd, Hill GB, Addison WA. Pelvic inflammatory disease: findings during inpatient treatment of clinically severe, laparoscopy-documented disease. Am J Obstet Gynecol 1992; 166:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35832/abstract/22\">",
"      Bevan CD, Ridgway GL, Rothermel CD. Efficacy and safety of azithromycin as monotherapy or combined with metronidazole compared with two standard multidrug regimens for the treatment of acute pelvic inflammatory disease. J Int Med Res 2003; 31:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35832/abstract/23\">",
"      Savaris RF, Teixeira LM, Torres TG, et al. Comparing ceftriaxone plus azithromycin or doxycycline for pelvic inflammatory disease: a randomized controlled trial. Obstet Gynecol 2007; 110:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35832/abstract/24\">",
"      Thompson SE, Brooks C, Eschenbach DA, et al. High failure rates in outpatient treatment of salpingitis with either tetracycline alone or penicillin/ampicillin combination. Am J Obstet Gynecol 1985; 152:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35832/abstract/25\">",
"      Brookoff D. Compliance with doxycycline therapy for outpatient treatment of pelvic inflammatory disease. South Med J 1994; 87:1088.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7585 Version 15.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.146-1B4384F6EC-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_63_35832=[""].join("\n");
var outline_f34_63_35832=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H16\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CANDIDATES FOR TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PATHOGENS OF CONCERN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1024892\">",
"      AVAILABLE ANTIMICROBIAL AGENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H412704\">",
"      CLINICAL TRIAL DATA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H412907\">",
"      Defining treatment response",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H412960\">",
"      Limitations of current data sets",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1224669\">",
"      - Clinical efficacy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1224676\">",
"      - Microbiologic efficacy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H412876\">",
"      Management of mild or moderate PID",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1024815\">",
"      INDICATIONS FOR HOSPITALIZATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      RECOMMENDED REGIMENS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H413108\">",
"      General approach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1025375\">",
"      Gonococcal drug resistance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1025421\">",
"      Role for anaerobic coverage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1025616\">",
"      Inpatient therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1025583\">",
"      - First-line therapies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2577820\">",
"      - Alternative regimens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H413397\">",
"      Outpatient therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2577827\">",
"      - First-line regimens",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Alternative agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H413492\">",
"      TREATMENT OF THE PENICILLIN-ALLERGIC PATIENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H414047\">",
"      Patients at risk for gonorrhea",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1225117\">",
"      - History of mild allergy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1225153\">",
"      - History of severe allergy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H414054\">",
"      Patients at low risk of gonorrhea",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H413500\">",
"      HIV-INFECTED PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      DURATION OF THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      PATIENT RELATED ISSUES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H413824\">",
"      Patient monitoring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Medication adherence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Counseling and screening",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Sex partners",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/0/1032?source=related_link\">",
"      Clinical features and diagnosis of pelvic inflammatory disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/55/20345?source=related_link\">",
"      Diagnostic assays for HIV infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/58/934?source=related_link\">",
"      Long-term complications of pelvic inflammatory disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/34/43560?source=related_link\">",
"      Management and complications of tuboovarian abscess",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/45/11992?source=related_link\">",
"      Pathogenesis of and risk factors for pelvic inflammatory disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?26/14/26850?source=related_link\">",
"      Patient information: Pelvic inflammatory disease (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/19/15672?source=related_link\">",
"      Penicillin-allergic patients: Use of cephalosporins, carbapenems, and monobactams",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/17/19738?source=related_link\">",
"      Recommendations for the use of human papillomavirus vaccines",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/3/19514?source=related_link\">",
"      Treatment of uncomplicated gonococcal infections",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_63_35833="PJS colonic polyp Light";
var content_f34_63_35833=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F69268&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F69268&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1108px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Colonic Peutz-Jeghers polyp",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 397px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Low power view of a colonic Peutz-Jeghers polyp shows a tree-like proliferation of smooth muscle lined by normal colonic cell types.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Robert Odze, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 518px\">",
"   <div class=\"ttl\">",
"    Normal colon",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 518px; height: 172px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Low (left) and high (right) power views of a biopsy of a normal colon. Low power reveals straight crypts and mild lamina propria mononuclear cell infiltration. High power shows the surface enterocytes with interspersed goblet cells (arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Robert Odze, MD",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_63_35833=[""].join("\n");
var outline_f34_63_35833=null;
var title_f34_63_35834="Cutaneous complications of molecularly targeted therapy and other biologic agents used for cancer therapy";
var content_f34_63_35834=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Cutaneous complications of molecularly targeted therapy and other biologic agents used for cancer therapy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/63/35834/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/63/35834/contributors\">",
"     Aimee S Payne, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/63/35834/contributors\">",
"     Diane MF Savarese, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/63/35834/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/63/35834/contributors\">",
"     Reed E Drews, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/63/35834/contributors\">",
"     Maja Mockenhaupt, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/63/35834/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/63/35834/contributors\">",
"     Rosamaria Corona, MD, DSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?34/63/35834/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 14, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Over the last two decades, novel antineoplastic therapy strategies have evolved that exploit some of the molecular abnormalities that have been detected in certain types of cancer. While the targets of these agents differ, collectively they are referred to as molecularly targeted agents. Many of these agents, particularly those interfering with signal transduction (eg, epidermal growth factor receptor [EGFR] inhibitors, multitargeted small molecule tyrosine kinase inhibitors), are associated with prominent and sometimes dose-limiting dermatologic complications.",
"   </p>",
"   <p>",
"    This topic review will cover dermatologic toxicities seen with several classes of biologic and molecularly-targeted agents, including drugs and monoclonal antibodies targeting the EGFR, other therapeutic monoclonal antibodies, small molecule tyrosine kinase inhibitors, and biologically active cytokines. Cutaneous reaction patterns seen with conventional cytotoxic agents are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/7/36986?source=see_link\">",
"     \"Cutaneous complications of conventional chemotherapy agents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EGFR SIGNAL TRANSDUCTION INHIBITORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The array of drugs that inhibit the epidermal growth factor receptor (EGFR) include two therapeutic monoclonal antibodies (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"     cetuximab",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/48/6918?source=see_link\">",
"     panitumumab",
"    </a>",
"    ) and three orally-active small molecule EGFR inhibitors (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/12/19654?source=see_link\">",
"     gefitinib",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/13/36056?source=see_link\">",
"     erlotinib",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/23/9592?source=see_link\">",
"     lapatinib",
"    </a>",
"    ). As a group, these drugs have prominent dermatologic side effects, the most common of which is a papulopustular acneiform eruption (",
"    <a class=\"graphic graphic_table graphicRef57215 \" href=\"mobipreview.htm?6/2/6187\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/32/44554?source=see_link\">",
"     \"Systemic chemotherapy for metastatic colorectal cancer: Completed clinical trials\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/27/11705?source=see_link\">",
"     \"Systemic treatment for metastatic breast cancer: Combination chemotherapy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/4/31816?source=see_link&amp;anchor=H177152529#H177152529\">",
"     \"Initial systemic therapy for advanced non-small cell lung cancer with a mutation in the epidermal growth factor receptor\", section on 'EGFR TKI toxicity'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Acneiform eruption",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common cutaneous reaction pattern with the EGFR inhibitors is a diffuse papulopustular acneiform eruption, which is noted in up to two-thirds of patients receiving any of these agents (although severe in only 5 to 10 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/63/35834/abstract/1-4\">",
"     1-4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Reactions, consisting of erythematous follicle-based papules and pustules, typically without comedones, are often dose-dependent and begin within one week after initiation of treatment (",
"    <a class=\"graphic graphic_picture graphicRef55753 \" href=\"mobipreview.htm?21/20/21827\">",
"     picture 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/63/35834/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. The lesions typically occur on the face, trunk, and extremities, sparing the palms and soles. Scaling of the interfollicular skin may also be present. Significant pruritus accompanies the cutaneous eruption in up to one-third of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/63/35834/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Biopsy of the lesions shows prominent keratin plugging in dilated infundibula of hair follicles, with or without a dense neutrophilic folliculitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/63/35834/abstract/2,8\">",
"     2,8",
"    </a>",
"    ]. In one case report, there was a complete absence of the follicular epithelial lining [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/63/35834/abstract/6\">",
"     6",
"    </a>",
"    ]. These reports are in agreement with mouse models of EGF inhibition, in which follicular inflammation with alopecia has been observed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/63/35834/abstract/9,10\">",
"     9,10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A single case report demonstrated sparing of previously irradiated skin from the acneiform rash, possibly due to radiation-induced loss of the hair follicle [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/63/35834/abstract/11\">",
"     11",
"    </a>",
"    ]. This raises the possibility that the follicle itself is involved in the initiation of this very common reaction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of various treatments for the acneic eruption is variable, and assessment of efficacy is complicated by the fact that some reactions spontaneously clear despite continued therapy with EGF pathway inhibitors. The response to topical acne treatments (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/24/42373?source=see_link\">",
"     benzoyl peroxide",
"    </a>",
"    , retinoids, and antibiotics) is inconsistent, although some benefit may be observed.",
"   </p>",
"   <p>",
"    The benefit of antibiotic administration after onset of rash has been addressed in an analysis of case reports and small case series of 11 to 24 patients, most of whom presented with grade 2 or worse folliculitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/63/35834/abstract/12\">",
"     12",
"    </a>",
"    ]. Treatment with a",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    with or without local topical agents was associated with a reduction in the severity of folliculitis in the vast majority of patients.",
"   </p>",
"   <p>",
"    Benefit has also been suggested in individual case reports for oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/62/1000?source=see_link\">",
"     isotretinoin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/63/35834/abstract/13,14\">",
"     13,14",
"    </a>",
"    ] and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/1/39958?source=see_link\">",
"     acitretin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/63/35834/abstract/15\">",
"     15",
"    </a>",
"    ]. Because of the potential for spontaneous clearing of the eruption, controlled studies are needed before these options can be routinely recommended.",
"   </p>",
"   <p>",
"    Oral H1 antihistamines, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/2/33824?source=see_link\">",
"     diphenhydramine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/24/391?source=see_link\">",
"     hydroxyzine",
"    </a>",
"    , or nonsedating agents may be beneficial for patients with pruritus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/63/35834/abstract/7,16\">",
"     7,16",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/28/33222?source=see_link\">",
"     Aprepitant",
"    </a>",
"    may also be beneficial. In a clinical trial, aprepitant (a neurokinin 1 receptor antagonist) was effective in reducing pruritus intensity by &gt;80 percent in 41 of 45 patients treated with EGFR and TK inhibitors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/63/35834/abstract/17\">",
"     17",
"    </a>",
"    ]. Pruritus did not recur in 87 percent of patients during the 90-day study period.",
"   </p>",
"   <p>",
"    Studies note a consistent positive correlation between the severity of the acneiform rash and antitumor activity, as manifested by the overall response rate and survival, for both monoclonal antibodies binding to the EGFR (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"     cetuximab",
"    </a>",
"    ) and small molecule inhibitors of the EGFR pathway (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/13/36056?source=see_link\">",
"     erlotinib",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/12/19654?source=see_link\">",
"     gefitinib",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/63/35834/abstract/18-21\">",
"     18-21",
"    </a>",
"    ]. The presence of an acneiform eruption is not a contraindication to continued therapy. In fact, there is some evidence that at least for cetuximab, dose escalation is safe and associated with a higher response rate in patients who have no or only a mild skin reaction within three weeks of starting therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/32/44554?source=see_link&amp;anchor=H56#H56\">",
"     \"Systemic chemotherapy for metastatic colorectal cancer: Completed clinical trials\", section on 'Cetuximab'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, for severe dermatologic reactions, dose modification guidelines are available for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"     cetuximab",
"    </a>",
"    &nbsp;(",
"    <a class=\"graphic graphic_table graphicRef58603 \" href=\"mobipreview.htm?36/61/37851\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Prophylactic therapy",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21260792\">",
"    <span class=\"h4\">",
"     Topical anti-acne therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are few trials that address the benefit of prophylactic topical anti-acne agents. In one published trial, 48 patients initiating",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"     cetuximab",
"    </a>",
"    for metastatic colorectal cancer were randomly assigned to apply",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/17/19732?source=see_link\">",
"     tazarotene",
"    </a>",
"    to either the right or left side of the face [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/63/35834/abstract/22\">",
"     22",
"    </a>",
"    ]. Prophylactic tazarotene was associated with significant skin irritation, was discontinued by one-third of patients, and provided little benefit beyond that seen with prophylactic oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/10/3240?source=see_link\">",
"     minocycline",
"    </a>",
"    (see below). &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21260800\">",
"    <span class=\"h4\">",
"     Systemic antibiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies evaluating prophylactic systemic antibiotics have yielded mixed results [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/63/35834/abstract/22-25\">",
"     22-25",
"    </a>",
"    ]. The efficacy of prophylactic",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    -type antibiotics for the prevention of EGFR inhibitor-induced acneiform eruption was evaluated in a systematic review [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/63/35834/abstract/12\">",
"     12",
"    </a>",
"    ] of four placebo-controlled randomized trials of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/10/3240?source=see_link\">",
"     minocycline",
"    </a>",
"    100 mg per day, tetracycline 500 mg twice a day, or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    100 mg once or twice a day [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/63/35834/abstract/22-24,26\">",
"     22-24,26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In all studies, treatment was started on the same day or the day before initiating EGFR inhibitor therapy and continued for four to six weeks; the control group consisted of either a placebo, the absence of treatment, or, in one study, reactive (after skin toxicity developed) management [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/63/35834/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a combined analysis, prophylactic treatment with a",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    was associated with a significant decrease in the incidence of moderate to severe (grade &ge;2) folliculitis (combined odds ratio 0.19, 95% CI 0.12-0.31), but not of mild (grade 1) folliculitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/63/35834/abstract/12\">",
"     12",
"    </a>",
"    ]. Benefit was lost upon treatment discontinuation. Three of the four studies also noted an improvement in quality of life in patients treated with preemptive antibiotics.",
"   </p>",
"   <p>",
"    The results of this meta-analysis suggest that prophylactic use of a",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    may be beneficial in decreasing the severity of the acneiform eruption in patients treated with EGFR inhibitor. Additionally, one trial (the randomized STEPP trial) demonstrated the superiority of preemptive sunscreens, moisturizers, topical steroids, and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    versus reactive therapy in patients receiving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/48/6918?source=see_link\">",
"     panitumumab",
"    </a>",
"    for advanced colorectal cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/63/35834/abstract/23\">",
"     23",
"    </a>",
"    ] (see",
"    <a class=\"local\" href=\"#H4\">",
"     'Treatment'",
"    </a>",
"    above). However, there are insufficient data to determine the optimal treatment regimen and duration. Additional studies with longer-term follow-up are needed. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Treatment'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Other reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the acneiform rash is the most prominent cutaneous adverse reaction, several other skin reactions are reported with anti-EGFR therapies (",
"    <a class=\"graphic graphic_table graphicRef57215 \" href=\"mobipreview.htm?6/2/6187\">",
"     table 1",
"    </a>",
"    ). Paronychial inflammation (often with pyogenic granuloma-like lesions) is a frequent side effect [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/63/35834/abstract/2,27,28\">",
"     2,27,28",
"    </a>",
"    ]. Paronychia involving the great toe is often the first sign (",
"    <a class=\"graphic graphic_picture graphicRef66462 \" href=\"mobipreview.htm?13/30/13796\">",
"     picture 2",
"    </a>",
"    ), and secondary bacterial infection (often with Staphylococcus aureus) is not uncommon [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/63/35834/abstract/29\">",
"     29",
"    </a>",
"    ]. Treatment options include topical antibiotics, topical corticosteroids,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    electrodesiccation for larger lesions.",
"   </p>",
"   <p>",
"    Other cutaneous complications reported with EGF pathway inhibitors include hair abnormalities (with scalp and extremity hair becoming brittle, finer and curly [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/63/35834/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]), trichomegaly and a marked increase in the length of the eyebrows [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/63/35834/abstract/30-32\">",
"     30-32",
"    </a>",
"    ], pruritus, xerosis with desquamation, small aphthous ulcerations of the oral and nasal mucosa, photosensitivity, and urticaria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/63/35834/abstract/2,27,33\">",
"     2,27,33",
"    </a>",
"    ]. This constellation of symptoms in addition to the acneiform eruption has been labeled the PRIDE syndrome (Papulopustules",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    paronychia, Regulatory abnormalities of hair growth, Itching, Dryness due to Epidermal growth factor receptor inhibitors).",
"   </p>",
"   <p>",
"    Bullous and exfoliative eruptions, including cases suggestive of Stevens-Johnson",
"    <span class=\"nowrap\">",
"     syndrome/toxic",
"    </span>",
"    epidermal necrolysis, have been associated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/13/36056?source=see_link\">",
"     erlotinib",
"    </a>",
"    therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/63/35834/abstract/34\">",
"     34",
"    </a>",
"    ]. However, no increased frequency was observed by the international Registry of Severe Cutaneous Adverse Reactions (RegiSCAR) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/63/35834/abstract/35\">",
"     35",
"    </a>",
"    ]. Although the prescribing information mentions that some cases have been fatal, a systematic review found no fatal reactions attributed to erlotinib,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"     cetuximab",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/48/6918?source=see_link\">",
"     panitumumab",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/63/35834/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. Discontinuation of erlotinib therapy is recommended if signs of these reactions occur.",
"   </p>",
"   <p>",
"    In addition, there is a single report of a necrolytic migratory erythema-like rash that responded to withdrawal of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/12/19654?source=see_link\">",
"     gefitinib",
"    </a>",
"    therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/63/35834/abstract/38\">",
"     38",
"    </a>",
"    ], a single case of small vessel vasculitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/63/35834/abstract/39\">",
"     39",
"    </a>",
"    ], and a small case series reporting xerosis, subcorneal pustules, and purpura without frank vasculitis on the lower extremities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/63/35834/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Given that EGFR signaling pathways are involved in cell proliferation, differentiation, survival, and repair [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/63/35834/abstract/41\">",
"     41",
"    </a>",
"    ], concern has been raised as to whether the inhibition of EGFR may contribute to increased cutaneous adverse reaction with concurrent exposure to ionizing radiation. Several reports, including a pooled retrospective analysis, have cited increased radiation-associated cutaneous adverse reactions in patients treated concomitantly with EGFR inhibitors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/63/35834/abstract/42-45\">",
"     42-45",
"    </a>",
"    ]. However, a trial involving 424 patients who were randomly assigned to radiotherapy with or without weekly",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"     cetuximab",
"    </a>",
"    did not confirm an increased risk of radiation dermatitis or mucositis in patients given both therapies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/63/35834/abstract/46\">",
"     46",
"    </a>",
"    ]. Further studies are necessary to clarify the impact of EGFR inhibitors on cutaneous complications related to radiation therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/15/29946?source=see_link&amp;anchor=H281027372#H281027372\">",
"     \"Locally advanced squamous cell carcinoma of the head and neck: Approaches combining chemotherapy and radiation therapy\", section on 'Epidermal growth factor inhibition'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A variety of cutaneous eruptions may also accompany acute infusion reactions to the therapeutic monoclonal antibody",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"     cetuximab",
"    </a>",
"    . &nbsp;(See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/19/38202?source=see_link&amp;anchor=H48#H48\">",
"     \"Infusion reactions to therapeutic monoclonal antibodies used for cancer therapy\", section on 'Cetuximab'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     SMALL MOLECULE KINASE SIGNAL TRANSDUCTION INHIBITORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several small molecules inhibit various kinase pathways, including:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The tyrosine kinase (TK) inhibitors",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"       imatinib",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?21/39/22136?source=see_link\">",
"       dasatinib",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/1/29720?source=see_link\">",
"       nilotinib",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?22/45/23254?source=see_link\">",
"       bosutinib",
"      </a>",
"      , which all inhibit signal transduction through the BCR-ABL fusion protein (which functions as a TK); some also inhibit KIT, the platelet-derived growth factor (PDGFR) family of TKs, and the SRC family of TKs.",
"     </li>",
"     <li>",
"      TK inhibitors that target the EGFR.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/45/9944?source=see_link\">",
"       Sorafenib",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?43/10/44200?source=see_link\">",
"       sunitinib",
"      </a>",
"      , TK inhibitors whose targets include PDGFR, KIT, vascular endothelial growth factor receptor (VEGFR), and Raf kinase (for sorafenib).",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?1/2/1064?source=see_link\">",
"       Pazopanib",
"      </a>",
"      , which targets multiple TKs including PDGFR-alpha and beta, VEGFR, and KIT.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/13/43222?source=see_link\">",
"       Axitinib",
"      </a>",
"      , which inhibits only&nbsp;VEGFR 1,2, and 3.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/16/32006?source=see_link\">",
"       Regorafenib",
"      </a>",
"      , which targets the TKs VEGFR1, 2, and 3 in addition to RET, KIT, PDGFR alpha and beta, fibroblast growth factor receptor (FGFR)1 and 2, and several other membrane-bound and intracellular kinases that are involved in normal cellular function and in pathologic processes.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/48/17159?source=see_link\">",
"       Vemurafenib",
"      </a>",
"      , which is not a TK inhibitor but is instead classified as a serine-threonine kinase inhibitor.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A number of cutaneous complications are described with these agents (",
"    <a class=\"graphic graphic_table graphicRef74634 \" href=\"mobipreview.htm?7/45/7900\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Imatinib",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"     Imatinib",
"    </a>",
"    is used for a variety of tumor types, most commonly, Philadelphia-chromosome-positive chronic myelogenous leukemia (Ph+CML, which are characterized by the presence of a fusion protein, BCR-ABL, that functions as a tyrosine-kinase) and gastrointestinal stromal tumors, which are characterized by KIT mutations. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/58/34730?source=see_link\">",
"     \"Tyrosine kinase inhibitor therapy for advanced gastrointestinal stromal tumors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/55/7034?source=see_link\">",
"     \"Initial treatment of chronic myeloid leukemia in chronic phase\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In early clinical trials, skin eruptions were reported in 22 percent of patients treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    , and up to 60 percent had edema, typically in a periorbital distribution [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/63/35834/abstract/47\">",
"     47",
"    </a>",
"    ]. The occurrence of eruptions is dose-dependent. The reported incidence is 33 percent at doses less than 400 mg daily and 93 percent with higher daily doses of 600 mg or more [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/63/35834/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Skin eruptions associated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    have multiple presentations, including:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The most common morphology is an exanthematous papular eruption. Although mild cases often resolve spontaneously over time despite drug continuation, more severe skin reactions require discontinuation of treatment for up to two weeks followed by reintroduction at a lower daily dose with or without a temporary course of an oral corticosteroid [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/63/35834/abstract/49,50\">",
"       49,50",
"      </a>",
"      ]. One successful reintroduction regimen involved an initial 100 mg daily dose of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"       imatinib",
"      </a>",
"      with weekly 100 mg dose escalations, without adjunctive use of oral corticosteroids.",
"     </li>",
"     <li>",
"      Other more severe reactions, including Stevens-Johnson syndrome (SJS), have been linked to higher initial doses of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"       imatinib",
"      </a>",
"      therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/63/35834/abstract/49,51\">",
"       49,51",
"      </a>",
"      ]. Severe skin rashes, especially SJS, usually prompt permanent drug discontinuation. However, there is a single case report of one patient with exfoliative dermatitis who had complete resolution of skin reaction when the regimen was decreased to once-weekly dosing [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/63/35834/abstract/52\">",
"       52",
"      </a>",
"      ]. Whether the once weekly dose regimen was sufficient for disease control was not reported.",
"     </li>",
"     <li>",
"      Acute generalized exanthematous pustulosis (AGEP) and Sweet syndrome (acute febrile neutrophilic dermatosis) have both been associated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"       imatinib",
"      </a>",
"      therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/63/35834/abstract/53-56\">",
"       53-56",
"      </a>",
"      ]. The skin lesions in AGEP generally resolve within two weeks [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/63/35834/abstract/57\">",
"       57",
"      </a>",
"      ]. In such cases, the decision as to whether to attempt retreatment with imatinib depends on the severity of the reaction, and whether there are other therapeutic alternatives. In one case of Sweet syndrome, the eruption resolved with oral glucocorticoid therapy and did not recur with reinitiation of imatinib, while in another case, recurrent skin lesions were observed with subsequent imatinib treatments.",
"     </li>",
"     <li>",
"      Photosensitization was described in a series of eight patients treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"       imatinib",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/63/35834/abstract/58\">",
"       58",
"      </a>",
"      ]. The incidence is low overall. In a prospective study of 54 patients treated with imatinib for CML, four (7 percent) developed photosensitivity [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/63/35834/abstract/48\">",
"       48",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A number of patients have noted pigmentary changes of the skin and hair while undergoing treatment with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"       imatinib",
"      </a>",
"      , including both hypopigmentation (in black patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/63/35834/abstract/59\">",
"       59",
"      </a>",
"      ]) and hyperpigmentation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/63/35834/abstract/59-63\">",
"       59-63",
"      </a>",
"      ]. As the KIT receptor is known to play a role in melanogenesis and melanocyte homeostasis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/63/35834/abstract/64\">",
"       64",
"      </a>",
"      ], the photosensitivity and pigmentary changes may represent direct physiologic responses by skin melanocytes.",
"     </li>",
"     <li>",
"      Induction of psoriasiform eruptions and exacerbations of psoriasis have occurred in patients treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"       imatinib",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/63/35834/abstract/48,65,66\">",
"       48,65,66",
"      </a>",
"      ]. In a prospective study of 54 patients treated with imatinib for CML, four developed a psoriasiform eruption; two had a known history of psoriasis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/63/35834/abstract/48\">",
"       48",
"      </a>",
"      ]. However, improvement of psoriasis has also been reported in one patient receiving imatinib for a gastrointestinal stromal tumor [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/63/35834/abstract/67\">",
"       67",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Other miscellaneous reactions that have been reported in patients receiving",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"       imatinib",
"      </a>",
"      include small vessel vasculitis, erythema nodosum, and a graft-versus-host-like skin reaction [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/63/35834/abstract/68\">",
"       68",
"      </a>",
"      ], an exfoliative dermatitis with fever and nonfollicular pustules [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/63/35834/abstract/48\">",
"       48",
"      </a>",
"      ], and a single report of hand-foot syndrome (see below) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/63/35834/abstract/69\">",
"       69",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10106591\">",
"    <span class=\"h2\">",
"     Dasatinib, nilotinib, and bosutinib",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/39/22136?source=see_link\">",
"     Dasatinib",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/1/29720?source=see_link\">",
"     nilotinib",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/45/23254?source=see_link\">",
"     bosutinib",
"    </a>",
"    are second generation multitargeted TK inhibitors which are only used for treatment of Ph+CML. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/17/20762?source=see_link\">",
"     \"Treatment of chronic myeloid leukemia in chronic phase after failure of initial therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    , several cutaneous effects are described (",
"    <a class=\"graphic graphic_table graphicRef74634 \" href=\"mobipreview.htm?7/45/7900\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a total of 911 patients reported in phase I and II studies of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?21/39/22136?source=see_link\">",
"       dasatinib",
"      </a>",
"      , cutaneous eruptions were reported in 35 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/63/35834/abstract/70\">",
"       70",
"      </a>",
"      ]. Reactions included localized and generalized erythema, papular eruptions, \"exfoliative rash\", and pruritus. The package insert notes \"frequent dermatologic adverse events, including hyperhidrosis, alopecia, xerosis, acne, urticaria, dermatitis, photosensitivity reaction, nail, and pigmentation disorders\". Two cases of dasatinib-induced panniculitis have been described [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/63/35834/abstract/71\">",
"       71",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In phase I and II studies, the most frequent nonhematologic side effects of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/1/29720?source=see_link\">",
"       nilotinib",
"      </a>",
"      were \"nonspecific rash\" (20 to 28 percent of all patients), pruritus (15 to 24 percent), and dry skin (12 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/63/35834/abstract/72,73\">",
"       72,73",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In clinical trials of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?22/45/23254?source=see_link\">",
"       bosutinib",
"      </a>",
"      , adverse skin reactions were reported in 20 to 44 percent of patients and included erythema, maculopapular eruption, pruritic rash, allergic dermatitis, acne, folliculitis, and skin exfoliation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/63/35834/abstract/74,75\">",
"       74,75",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Sorafenib and sunitinib",
"    </span>",
"    &nbsp;&mdash;&nbsp;The multitargeted TK inhibitors",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/10/44200?source=see_link\">",
"     sunitinib",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/45/9944?source=see_link\">",
"     sorafenib",
"    </a>",
"    are associated with a variety of cutaneous effects. The most common is a hand-foot skin reaction, which differs in its clinical presentation and histologic appearance from the acral erythema caused by other conventional chemotherapy drugs (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/7/36986?source=see_link&amp;anchor=H23#H23\">",
"     \"Cutaneous complications of conventional chemotherapy agents\", section on 'Acral erythema (hand-foot skin reaction)'",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Hand-foot skin reaction",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical and histologic appearance of the hand-foot skin reaction (HFSR) seen with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/45/9944?source=see_link\">",
"     sorafenib",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/10/44200?source=see_link\">",
"     sunitinib",
"    </a>",
"    and other agents targeting VEGFR, differs from the classic form of acral erythema. Acral erythema is most often characterized by a symmetric edema and erythema of the palms and soles which may progress to blistering and necrosis, with loss of the epidermis and crusting. In contrast, patients treated with sunitinib or sorafenib develop localized tender lesions, which appear as blisters or hyperkeratosis in areas of trauma or friction (",
"    <a class=\"graphic graphic_picture graphicRef81824 \" href=\"mobipreview.htm?32/35/33328\">",
"     picture 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/63/35834/abstract/63,76-79\">",
"     63,76-79",
"    </a>",
"    ]. Some patients also have involvement of the lateral sides of the fingers and the periungual regions, with extension to the dorsal surfaces of the hands and feet. Others report hemorrhagic bullae on the elbows as well [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/63/35834/abstract/76\">",
"     76",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hyperkeratosis is frequent, developing in over one-half of affected patients; in some cases, it is the only manifestation of HFSR [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/63/35834/abstract/63\">",
"     63",
"    </a>",
"    ]. The hyperkeratosis typically presents as yellowish, painful, hyperkeratotic plaques localized to the pressure sole areas (heels and metatarsals). Hyperkeratosis is less frequently reported in classic acral erythema, where it occurs mostly during the chronic phase of the disease.",
"   </p>",
"   <p>",
"    As with acral erythema, symptoms may include paresthesia, tingling, burning, and painful sensations on the palms and soles, as well as decreased tolerance to contact with hot objects. Symptoms generally start within the first two to four weeks of therapy. Subjective signs usually precede cutaneous lesions.",
"   </p>",
"   <p>",
"    The frequency of HFSR appears to be higher with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/45/9944?source=see_link\">",
"     sorafenib",
"    </a>",
"    (30 to 60 percent) than with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/10/44200?source=see_link\">",
"     sunitinib",
"    </a>",
"    (10 to 20 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/63/35834/abstract/63,76-78,80-83\">",
"     63,76-78,80-83",
"    </a>",
"    ]. In addition, phase I studies have shown an increased frequency and severity of HFSR with higher doses and with increased cumulative exposure of sorafenib, but this has not been observed with sunitinib [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/63/35834/abstract/84-86\">",
"     84-86",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Histologic examination of the affected skin has been performed on few patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/63/35834/abstract/63,76\">",
"     63,76",
"    </a>",
"    ]. The findings include epidermal parakeratosis and dyskeratosis with bandlike areas of necrotic keratinocytes. The dermis contains a dense, superficial perivascular lymphocytic infiltrate; at least one report notes some degree of nonleucocytoclastic vasculitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/63/35834/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The pathogenesis of HFSR with this drug class is not yet established. The capillary endothelium may be the first target in HFSR, as both",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/10/44200?source=see_link\">",
"     sunitinib",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/45/9944?source=see_link\">",
"     sorafenib",
"    </a>",
"    enhance tumor vessel regression via inhibition of endothelial cell survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/63/35834/abstract/87\">",
"     87",
"    </a>",
"    ], and the addition of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    , a monoclonal antibody targeting vascular endothelial growth factor (VEGF), to sorafenib appears to enhance HFSR [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/63/35834/abstract/86,88\">",
"     86,88",
"    </a>",
"    ]. It is possible that alterations of specific small vessels that are commonly traumatized by frequent impact (nails) or pressure (contact areas of the palms, soles) require continuous endothelial repair involving the VEGF receptor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/63/35834/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are no randomized trials to determine the best management strategy for HFSR. The following represent a compilation of expert opinion from an international consensus group [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/63/35834/abstract/89\">",
"     89",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Before therapy begins, preexisting hyperkeratotic areas and calluses should be removed through a manicure",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      pedicure, using appropriately sterilized instruments.",
"     </li>",
"     <li>",
"      Evaluation by an orthotist for an orthotic device is encouraged for patients with evidence of abnormal weight bearing.",
"     </li>",
"     <li>",
"      Exposure of hands and feet to hot water should be avoided, as this is believed to exacerbate symptoms.",
"     </li>",
"     <li>",
"      Avoid constrictive footwear, and excessive friction on the skin when applying lotions, getting massages or performing everyday tasks such as typing or using handheld electronic devices [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/63/35834/abstract/77\">",
"       77",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Vigorous exercise that places undue stress on the palms",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      soles of the feet should be avoided, particularly during the first month of therapy.",
"     </li>",
"     <li>",
"      Shoes with padded insoles should be worn throughout treatment to reduce pressure on the feet. Thick cotton gloves or socks can be worn to prevent injury and keep the palms and soles dry.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For patients who develop an HFSR while receiving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/10/44200?source=see_link\">",
"     sunitinib",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/45/9944?source=see_link\">",
"     sorafenib",
"    </a>",
"    , the following management strategies were suggested by this group [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/63/35834/abstract/89\">",
"     89",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For mild (grade 1, (",
"      <a class=\"graphic graphic_table graphicRef82460 \" href=\"mobipreview.htm?9/56/10123\">",
"       table 4",
"      </a>",
"      )) symptoms, dose modifications are not needed. Hot water should be avoided, and the use of topical emollients encouraged. Keratolytics, such as urea (20 to 40 percent), or salicylic acid (6 to 10 percent) may be indicated.",
"     </li>",
"     <li>",
"      For grade 2 HFSR, treatment should continue as for grade 1 HFSR, but with the addition of a topical corticosteroid (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/16/10502?source=see_link\">",
"       clobetasol",
"      </a>",
"      0.05 percent ointment) to the erythematous areas twice daily. Topical analgesics such as 2 percent",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"       lidocaine",
"      </a>",
"      may suffice for discomfort. If necessary, the dose of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/45/9944?source=see_link\">",
"       sorafenib",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?43/10/44200?source=see_link\">",
"       sunitinib",
"      </a>",
"      can be temporarily reduced to 50 percent for at least seven days, until the HFSR reaches grade 0 or 1, then resume full dosing.",
"     </li>",
"     <li>",
"      For grade 3 HFSR, treatment should be provided as for grade 1 or 2 HFSR, with temporary discontinuation of the drug for at least seven days until the grade of severity is reduced to 0 or 1. Treatment should be resumed at 50 percent of the usual dose. If the adverse reaction does not recur, dose escalation can be attempted.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If the clinical picture is limited to hyperkeratotic, tender lesions, topical agents that inhibit keratinocyte proliferation may be helpful, including urea 40 percent cream,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/17/19732?source=see_link\">",
"     tazarotene",
"    </a>",
"    0.1 percent cream, or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/32/33280?source=see_link\">",
"     fluorouracil",
"    </a>",
"    5 percent cream [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/63/35834/abstract/76,81,89\">",
"     76,81,89",
"    </a>",
"    ]. These agents should be applied twice daily to affected areas only.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Squamoproliferative lesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/45/9944?source=see_link\">",
"     Sorafenib",
"    </a>",
"    has been associated with cutaneous squamoproliferative lesions, including keratoacanthomas (KA) and squamous cell carcinomas (SCC) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/63/35834/abstract/90-95\">",
"     90-95",
"    </a>",
"    ]. In a retrospective study of 131 patients receiving sorafenib for metastatic renal cell carcinoma, seven were diagnosed with SCC and two with KA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/63/35834/abstract/91\">",
"     91",
"    </a>",
"    ]. Another report described the appearance of 22 squamoproliferative lesions in 13 patients within nine months of initiating sorafenib [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/63/35834/abstract/90\">",
"     90",
"    </a>",
"    ]. One was described as a classic invasive SCC, five as KA-like SCC, and 16 as classic KA. Prospective studies are necessary to clarify the risk and natural history of sorafenib induced squamoproliferative lesions.",
"   </p>",
"   <p>",
"    Squamoproliferative lesions that develop during",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/45/9944?source=see_link\">",
"     sorafenib",
"    </a>",
"    therapy should be treated similarly to lesions that develop in patients not receiving the drug (usually with complete surgical excision). However, spontaneous regression of KAs has been reported after discontinuation of the drug, and also in a few patients who continued therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/63/35834/abstract/90,96\">",
"     90,96",
"    </a>",
"    ]. Definitive guidelines for continuing versus discontinuing sorafenib in patients who develop SCC or KAs while on therapy have not been established. Close clinical follow-up during treatment is warranted. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/30/31209?source=see_link\">",
"     \"Treatment and prognosis of cutaneous squamous cell carcinoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Other effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other cutaneous adverse effects seen with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/45/9944?source=see_link\">",
"     sorafenib",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/10/44200?source=see_link\">",
"     sunitinib",
"    </a>",
"    include seborrheic dermatitis-like facial and scalp erythema, scalp dysesthesia, temporary alopecia, and subungual splinter hemorrhages [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/63/35834/abstract/81,97\">",
"     81,97",
"    </a>",
"    ]. Hair depigmentation (which is reversible when treatment is discontinued or during a treatment washout period) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/63/35834/abstract/85\">",
"     85",
"    </a>",
"    ], yellow skin discoloration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/63/35834/abstract/70\">",
"     70",
"    </a>",
"    ], eruptive melanocytic lesions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/63/35834/abstract/98\">",
"     98",
"    </a>",
"    ], Stevens-Johnson syndrome , mucositis, periungual erythema [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/63/35834/abstract/99\">",
"     99",
"    </a>",
"    ], xerosis, and exanthematous rashes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/63/35834/abstract/100\">",
"     100",
"    </a>",
"    ] have also been reported.",
"   </p>",
"   <p>",
"    Pyoderma gangrenosum, a rare noninfectious neutrophilic dermatosis, has been reported in patients receiving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/10/44200?source=see_link\">",
"     sunitinib",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/63/35834/abstract/101-103\">",
"     101-103",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is unknown whether",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/45/9944?source=see_link\">",
"     sorafenib",
"    </a>",
"    stimulates the development of other epithelial skin cancers. A possible association between sorafenib and basal cell carcinoma has been reported in two patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/63/35834/abstract/104\">",
"     104",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H91378765\">",
"    <span class=\"h2\">",
"     Pazopanib",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/2/1064?source=see_link\">",
"     Pazopanib",
"    </a>",
"    is a multitargeted TK inhibitor used in the treatment of advanced renal cell carcinoma and soft tissue sarcoma. Changes in hair color or skin color may occur during treatment with this drug. In a phase III trial in which 290 patients with renal cell carcinoma were treated with pazopanib, changes in hair color occurred in 38 percent of treated patients and skin hypopigmentation was noted in 3 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/63/35834/abstract/105\">",
"     105",
"    </a>",
"    ]. As with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    , it is postulated that pigmentary changes associated with pazopanib may result from alterations in melanocyte proliferation or function secondary to the inhibition of KIT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/63/35834/abstract/106\">",
"     106",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Imatinib'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Other potential side effects of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/2/1064?source=see_link\">",
"     pazopanib",
"    </a>",
"    reported in the trial included alopecia (8 percent), rash (8 percent), and hand-foot skin reaction (HFSR) (6 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/63/35834/abstract/105,107\">",
"     105,107",
"    </a>",
"    ]. In a meta-analysis of 10 trials (1163 patients), the frequency of all-grade HFSR was 4.5 percent (95% CI 2.5-7.9 percent), significantly lower than that historically observed for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/45/9944?source=see_link\">",
"     sorafenib",
"    </a>",
"    (30 to 60 percent) and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/10/44200?source=see_link\">",
"     sunitinib",
"    </a>",
"    (10 to 20 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/63/35834/abstract/108\">",
"     108",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Hand-foot skin reaction'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31257041\">",
"    <span class=\"h2\">",
"     Axitinib",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/13/43222?source=see_link\">",
"     Axitinib",
"    </a>",
"    is an orally available potent inhibitor of the VEGFR 1, 2, and 3 that is approved for the treatment of advanced renal cell carcinoma. In a meta-analysis of six trials including 984 patients, the incidence of all-grade and high-grade HFSR was 29.2&nbsp;percent (95% CI 14.0-51.1&nbsp;percent) and 9.6&nbsp;percent (95% CI 4.2-20.7&nbsp;percent), respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/63/35834/abstract/109\">",
"     109",
"    </a>",
"    ]. The incidence of HFSR and other cutaneous adverse reactions (including alopecia) seems to be significantly lower with axitinib than",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/45/9944?source=see_link\">",
"     sorafenib",
"    </a>",
"    . In a phase III trial in which 359 patients with renal carcinoma were randomly assigned to axitinib and 355 to sorafenib, HFSR occurred in 27 and 51 percent of patients treated with axitinib and sorafenib, respectively; skin eruption in 13 versus 32 percent; and alopecia in 4 versus 32 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/63/35834/abstract/97\">",
"     97",
"    </a>",
"    ]. The skin eruption associated with axitinib is typically macular-papular, mildly pruritic, and not dose-limiting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22183968\">",
"    <span class=\"h2\">",
"     Vandetanib",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/42/17063?source=see_link\">",
"     Vandetanib",
"    </a>",
"    is another multitargeted orally active inhibitor of several tyrosine kinases including RET, VEGFR, and EGFR. In clinical trials involving patients with medullary thyroid cancer and lung cancer, skin reactions (manifest as dermatitis, acneiform eruption, dry skin, pruritus, photosensitivity, or hand-foot skin reaction) have been reported in 28 to 71 percent of patients; they were severe (grade 3 or worse) in 3 to 6 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/63/35834/abstract/110-115\">",
"     110-115",
"    </a>",
"    ]. Paronychia, genital eruptions resembling intertrigo, photodistributed lichenoid drug eruption, and subacute cutaneous lupus erythematosus also have been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/63/35834/abstract/116\">",
"     116",
"    </a>",
"    ]. Severe skin reactions (including Stevens-Johnson syndrome), some leading to death, have been reported with this agent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/63/35834/abstract/117,118\">",
"     117,118",
"    </a>",
"    ]. Patients should be counseled to wear sunscreen and protective clothing when exposed to the sun.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11564980\">",
"    <span class=\"h2\">",
"     Regorafenib",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/16/32006?source=see_link\">",
"     Regorafenib",
"    </a>",
"    targets VEGFR 1, 2, and 3 in addition to RET, KIT, PDGFR alpha and beta, fibroblast growth factor receptor (FGFR) 1 and 2, and several other membrane-bound and intracellular kinases that are involved in normal cellular function and in pathologic processes. It is approved in the United States for treatment of refractory metastatic colorectal cancer. In a placebo-controlled phase III trial (the CORRECT trial), HFSR was reported in 47 percent of patients treated with regorafenib (versus 8 percent in the placebo group), and it was severe (grade 3) in 17 versus &lt;1 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/63/35834/abstract/119\">",
"     119",
"    </a>",
"    ].",
"    <span class=\"nowrap\">",
"     Rash/desquamation",
"    </span>",
"    was reported in 26 percent (versus 4 percent with placebo), and it was severe in 6 versus 0 percent. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/32/44554?source=see_link&amp;anchor=H56909045#H56909045\">",
"     \"Systemic chemotherapy for metastatic colorectal cancer: Completed clinical trials\", section on 'Regorafenib'",
"    </a>",
"    .) &nbsp; &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3204039\">",
"    <span class=\"h2\">",
"     Vemurafenib",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/48/17159?source=see_link\">",
"     Vemurafenib",
"    </a>",
"    , an orally available potent inhibitor of the kinase domain in mutant BRAF (a serine-threonine kinase), is approved for treatment of metastatic melanoma with a V600E BRAF mutation. In clinical trials, adverse skin reactions were common and included rash (18 percent); photosensitivity (12 percent); squamous cell carcinoma, keratoacanthoma, or both (18 to 24 percent); and alopecia (8 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/63/35834/abstract/120,121\">",
"     120,121",
"    </a>",
"    ]. The cutaneous squamous cell carcinomas were managed with excision, and patients were able to continue treatment without dose adjustment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/63/35834/abstract/122\">",
"     122",
"    </a>",
"    ]. &nbsp;(See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/30/19944?source=see_link\">",
"     \"Molecularly targeted therapy for metastatic melanoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The phototoxic reaction reported in patients taking",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/48/17159?source=see_link\">",
"     vemurafenib",
"    </a>",
"    appears to be caused by UVA radiation and may be prevented with the use of broad spectrum sunscreens (",
"    <a class=\"graphic graphic_table graphicRef58215 \" href=\"mobipreview.htm?8/51/9019\">",
"     table 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/63/35834/abstract/123\">",
"     123",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     OTHER THERAPEUTIC MONOCLONAL ANTIBODIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Therapeutic monoclonal antibodies that target molecules other than EGFR are well tolerated from a dermatologic perspective, although infusion reactions can include cutaneous manifestations (",
"    <a class=\"graphic graphic_table graphicRef66971 \" href=\"mobipreview.htm?3/4/3147\">",
"     table 6",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H2\">",
"     'EGFR signal transduction inhibitors'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Infusion reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infusion reactions are relatively frequent with certain therapeutic monoclonal antibodies, including",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"     cetuximab",
"    </a>",
"    , gemtuzumab, and intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/25/26008?source=see_link\">",
"     alemtuzumab",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Infusion reactions, which commonly include skin rash, typically develop within 30 minutes to two hours after the initiation of drug infusion, although symptoms may be delayed for up to 24 hours. The majority of reactions occur after the first or second exposure to the agent. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/19/38202?source=see_link\">",
"     \"Infusion reactions to therapeutic monoclonal antibodies used for cancer therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Serum sickness",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serum sickness (a delayed type III allergic reaction, (",
"    <a class=\"graphic graphic_table graphicRef71375 \" href=\"mobipreview.htm?13/23/13692\">",
"     table 7",
"    </a>",
"    )) has been reported with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    . Symptoms include fever, arthralgia, with a morbilliform skin eruption that often has acral accentuation. The reaction typically develops one to two weeks after treatment and is accompanied by laboratory evidence of complement activation (depressed C3 and C4 levels) and tissue inflammation (elevated erythrocyte sedimentation rate and C-reactive protein). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/19/38202?source=see_link&amp;anchor=H19#H19\">",
"     \"Infusion reactions to therapeutic monoclonal antibodies used for cancer therapy\", section on 'Rituximab'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Besides",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    , serum sickness has also been reported with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/25/26008?source=see_link\">",
"     alemtuzumab",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/40/8842?source=see_link\">",
"     \"Serum sickness and serum sickness-like reactions\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Other reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Besides those occurring in the setting of an infusion reaction, mild \"nonspecific skin rashes\" have been reported in patients treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/52/19270?source=see_link\">",
"     ipilimumab",
"    </a>",
"    , gemtuzumab,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/25/26008?source=see_link\">",
"     alemtuzumab",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/61/25557?source=see_link\">",
"     pertuzumab",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/63/35834/abstract/124-129\">",
"     124-129",
"    </a>",
"    ]. Pruritus, rash, vitiligo, alopecia, and more severe skin reactions have been reported in about 40 percent of patients with advanced melanoma treated with ipilimumab [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/63/35834/abstract/127\">",
"     127",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/28/2506?source=see_link\">",
"     \"Advanced melanoma: anti-CTLA-4 antibodies and other immune checkpoint strategies\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some of the other less common specific cutaneous reactions associated with therapeutic monoclonal antibodies used for cancer therapy include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cutaneous herpes simplex infections with gemtuzumab (21 percent incidence in early clinical trials [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/63/35834/abstract/130\">",
"       130",
"      </a>",
"      ]).",
"     </li>",
"     <li>",
"      Treatment with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/25/26008?source=see_link\">",
"       alemtuzumab",
"      </a>",
"      increases the risk for viral reactivation, including cytomegalovirus [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/63/35834/abstract/131\">",
"       131",
"      </a>",
"      ]. Cutaneous cytomegalovirus reactivation clinically presents as an erythematous exanthem, although skin biopsy can show typical cytological viral changes and the presence of viral particles on immunohistochemistry, confirming this diagnosis.",
"     </li>",
"     <li>",
"      Stevens-Johnson syndrome, toxic epidermal necrolysis, and full thickness necrosis have been reported in a small number of patients treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?18/52/19270?source=see_link\">",
"       ipilimumab",
"      </a>",
"      for metastatic melanoma [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/63/35834/abstract/132,133\">",
"       132,133",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?2/28/2506?source=see_link&amp;anchor=H600390149#H600390149\">",
"       \"Advanced melanoma: anti-CTLA-4 antibodies and other immune checkpoint strategies\", section on 'Dermatitis'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     CYTOKINE AGENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Injection site reactions are common with injectable cytokines, most of which are mild and self-limiting. More specific cutaneous reactions reflecting the immunomodulatory nature of individual cytokine therapies are discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Colony stimulating factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/13/23767?source=see_link\">",
"     Granulocyte colony-stimulating factor",
"    </a>",
"    (G-CSF) and granulocyte-macrophage colony stimulating factor (GM-CSF) have been associated with a variety of neutrophilic dermatoses, including Sweet syndrome (acute febrile neutrophilic dermatosis), bullous pyoderma gangrenosum, psoriasis, and leukocytoclastic vasculitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/63/35834/abstract/134,135\">",
"     134,135",
"    </a>",
"    ]. In addition, GM-CSF has been associated with generalized exanthems. The morphology is variable and can include maculopapular, pustular, urticarial, purpuric, and exfoliative eruptions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Interferons",
"    </span>",
"    &nbsp;&mdash;&nbsp;The alpha and gamma isoforms of interferon are most commonly used in cancer therapy. As expected from their immunologic activity, interferons are associated with worsening of a variety of cutaneous inflammatory and autoimmune diseases including allergic contact dermatitis, psoriasis, cutaneous lupus, and pemphigus, among others.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Interleukin-2",
"    </span>",
"    &nbsp;&mdash;&nbsp;Interleukin 2 is frequently associated with cutaneous erythema, which may progress to erythroderma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/63/35834/abstract/136\">",
"     136",
"    </a>",
"    ]. This is probably due to systemic vasodilation. Severe bullous eruptions resembling toxic epidermal necrolysis have also been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/63/35834/abstract/137,138\">",
"     137,138",
"    </a>",
"    ]. Exacerbation of inflammatory and autoimmune disorders also occurs, and this can be manifested by vitiligo, pemphigus, dermatomyositis, or psoriasis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H757138\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Treatment with epidermal growth factor receptor (EGFR) inhibitors (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"       cetuximab",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/48/6918?source=see_link\">",
"       panitumumab",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/12/19654?source=see_link\">",
"       gefitinib",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/13/36056?source=see_link\">",
"       erlotinib",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/23/9592?source=see_link\">",
"       lapatinib",
"      </a>",
"      ) is frequently associated with cutaneous side effects (",
"      <a class=\"graphic graphic_table graphicRef57215 \" href=\"mobipreview.htm?6/2/6187\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'EGFR signal transduction inhibitors'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      A diffuse papulopustular acneiform eruption occurs in up to two-thirds of patients receiving EGFR. The eruption, consisting of erythematous follicle-based papules and pustules, typically without comedones, begins within one week after initiation of treatment and is often dose-dependent (",
"      <a class=\"graphic graphic_picture graphicRef55753 \" href=\"mobipreview.htm?21/20/21827\">",
"       picture 1",
"      </a>",
"      ). We suggest prophylactic therapy with a",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/49/2840?source=see_link\">",
"       tetracycline",
"      </a>",
"      -type antibiotic (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Prophylactic therapy with an oral tetracycline-type antibiotic can reduce the severity of the skin eruption. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Acneiform eruption'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Treatment'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5\">",
"       'Prophylactic therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Small molecule tyrosine kinase inhibitors (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"       imatinib",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/45/9944?source=see_link\">",
"       sorafenib",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?43/10/44200?source=see_link\">",
"       sunitinib",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/16/32006?source=see_link\">",
"       regorafenib",
"      </a>",
"      ) are also associated with a variety cutaneous adverse effects (",
"      <a class=\"graphic graphic_table graphicRef74634 \" href=\"mobipreview.htm?7/45/7900\">",
"       table 3",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Small molecule kinase signal transduction inhibitors'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Treatment with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"       imatinib",
"      </a>",
"      is most frequently associated with an exanthematous papular eruption. Severe reactions are rare and include Stevens-Johnson syndrome, acute generalized exanthematous pustulosis, and Sweet syndrome (acute febrile neutrophilic dermatosis). Photosensitization, hypo - or hyperpigmentation, and exacerbation of psoriasis have also been reported. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Imatinib'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most common adverse effect of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/45/9944?source=see_link\">",
"       sorafenib",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?43/10/44200?source=see_link\">",
"       sunitinib",
"      </a>",
"      is a hand-foot skin reaction characterized by tender lesions, blisters, or hyperkeratosis in areas of trauma or friction (",
"      <a class=\"graphic graphic_picture graphicRef81824 \" href=\"mobipreview.htm?32/35/33328\">",
"       picture 3",
"      </a>",
"      ). Additional symptoms include paresthesias, tingling, burning, and painful sensations on the palms and soles, and decreased tolerance to contact with hot objects. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Hand-foot skin reaction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/45/9944?source=see_link\">",
"       Sorafenib",
"      </a>",
"      has also been associated with cutaneous squamoproliferative lesions, including keratoacanthomas and squamous cell carcinomas. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Squamoproliferative lesions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Other cutaneous adverse effects of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/45/9944?source=see_link\">",
"       sorafenib",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?43/10/44200?source=see_link\">",
"       sunitinib",
"      </a>",
"      include seborrheic dermatitis-like facial and scalp erythema, scalp dysesthesia, temporary alopecia, and subungual splinter hemorrhages, hair depigmentation, and yellow skin discoloration. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Other effects'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Infusion reactions have been reported with therapeutic monoclonal antibodies (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"       cetuximab",
"      </a>",
"      , gemtuzumab, and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/25/26008?source=see_link\">",
"       alemtuzumab",
"      </a>",
"      ) (",
"      <a class=\"graphic graphic_table graphicRef66971 \" href=\"mobipreview.htm?3/4/3147\">",
"       table 6",
"      </a>",
"      ). These reactions develop within 30 minutes to two hours after the initiation of drug infusion, often after the first or second exposure to the agent. &nbsp;(See",
"      <a class=\"local\" href=\"#H14\">",
"       'Other therapeutic monoclonal antibodies'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H15\">",
"       'Infusion reactions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Severe skin reactions, including Sweet syndrome, bullous pyoderma gangrenosum, psoriasis, and leukocytoclastic vasculitis, have been reported with cytokine agents such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/13/23767?source=see_link\">",
"       granulocyte colony-stimulating factor",
"      </a>",
"      and granulocyte-macrophage colony stimulating factor. Interferons are frequently associated with worsening of cutaneous inflammatory and autoimmune diseases including allergic contact dermatitis, psoriasis, cutaneous lupus, and pemphigus. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Cytokine agents'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35834/abstract/1\">",
"      Jacot W, Bessis D, Jorda E, et al. Acneiform eruption induced by epidermal growth factor receptor inhibitors in patients with solid tumours. Br J Dermatol 2004; 151:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35834/abstract/2\">",
"      Busam KJ, Capodieci P, Motzer R, et al. Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225. Br J Dermatol 2001; 144:1169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35834/abstract/3\">",
"      Moy B, Goss PE. Lapatinib-associated toxicity and practical management recommendations. Oncologist 2007; 12:756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35834/abstract/4\">",
"      Jatoi A, Green EM, Rowland KM Jr, et al. Clinical predictors of severe cetuximab-induced rash: observations from 933 patients enrolled in north central cancer treatment group study N0147. Oncology 2009; 77:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35834/abstract/5\">",
"      Kimyai-Asadi A, Jih MH. Follicular toxic effects of chimeric anti-epidermal growth factor receptor antibody cetuximab used to treat human solid tumors. Arch Dermatol 2002; 138:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35834/abstract/6\">",
"      Van Doorn R, Kirtschig G, Scheffer E, et al. Follicular and epidermal alterations in patients treated with ZD1839 (Iressa), an inhibitor of the epidermal growth factor receptor. Br J Dermatol 2002; 147:598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35834/abstract/7\">",
"      Li T, Perez-Soler R. Skin toxicities associated with epidermal growth factor receptor inhibitors. Target Oncol 2009; 4:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35834/abstract/8\">",
"      Albanell J, Rojo F, Averbuch S, et al. Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition. J Clin Oncol 2002; 20:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35834/abstract/9\">",
"      Murillas R, Larcher F, Conti CJ, et al. Expression of a dominant negative mutant of epidermal growth factor receptor in the epidermis of transgenic mice elicits striking alterations in hair follicle development and skin structure. EMBO J 1995; 14:5216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35834/abstract/10\">",
"      Hansen LA, Alexander N, Hogan ME, et al. Genetically null mice reveal a central role for epidermal growth factor receptor in the differentiation of the hair follicle and normal hair development. Am J Pathol 1997; 150:1959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35834/abstract/11\">",
"      Yal&ccedil;in S, Dizdar O, Yal&ccedil;in B, G&ouml;k&ouml;z O. Sparing of previously irradiated skin from erlotinib-induced acneiform rash. J Am Acad Dermatol 2008; 58:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35834/abstract/12\">",
"      Bachet JB, Peuvrel L, Bachmeyer C, et al. Folliculitis induced by EGFR inhibitors, preventive and curative efficacy of tetracyclines in the management and incidence rates according to the type of EGFR inhibitor administered: a systematic literature review. Oncologist 2012; 17:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35834/abstract/13\">",
"      DeWitt CA, Siroy AE, Stone SP. Acneiform eruptions associated with epidermal growth factor receptor-targeted chemotherapy. J Am Acad Dermatol 2007; 56:500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35834/abstract/14\">",
"      Gutzmer R, Werfel T, Mao R, et al. Successful treatment with oral isotretinoin of acneiform skin lesions associated with cetuximab therapy. Br J Dermatol 2005; 153:849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35834/abstract/15\">",
"      Pomerantz RG, Chirinos RE, Falo LD Jr, Geskin LJ. Acitretin for treatment of EGFR inhibitor-induced cutaneous toxic effects. Arch Dermatol 2008; 144:949.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35834/abstract/16\">",
"      Potthoff K, Hofheinz R, Hassel JC, et al. Interdisciplinary management of EGFR-inhibitor-induced skin reactions: a German expert opinion. Ann Oncol 2011; 22:524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35834/abstract/17\">",
"      Santini D, Vincenzi B, Guida FM, et al. Aprepitant for management of severe pruritus related to biological cancer treatments: a pilot study. Lancet Oncol 2012; 13:1020.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35834/abstract/18\">",
"      Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35834/abstract/19\">",
"      Per&eacute;z-Soler R, Saltz L. Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining? J Clin Oncol 2005; 23:5235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35834/abstract/20\">",
"      Agero AL, Dusza SW, Benvenuto-Andrade C, et al. Dermatologic side effects associated with the epidermal growth factor receptor inhibitors. J Am Acad Dermatol 2006; 55:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35834/abstract/21\">",
"      Perez-Soler R. Rash as a surrogate marker for efficacy of epidermal growth factor receptor inhibitors in lung cancer. Clin Lung Cancer 2006; 8 Suppl 1:S7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35834/abstract/22\">",
"      Scope A, Agero AL, Dusza SW, et al. Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption. J Clin Oncol 2007; 25:5390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35834/abstract/23\">",
"      Lacouture ME, Mitchell EP, Piperdi B, et al. Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-Emptive Skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer. J Clin Oncol 2010; 28:1351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35834/abstract/24\">",
"      Deplanque G, Chavaillon J, Vergnenegre A. CYTAR: A randomized clinical trial evaluating the preventive effect of doxycycline on erlotinib-induced folliculitis in non-small cell lung cancer patients. J Clin Oncol 2010; 28:640s.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35834/abstract/25\">",
"      Jatoi A, Dakhil SR, Sloan JA, et al. Prophylactic tetracycline does not diminish the severity of epidermal growth factor receptor (EGFR) inhibitor-induced rash: results from the North Central Cancer Treatment Group (Supplementary N03CB). Support Care Cancer 2011; 19:1601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35834/abstract/26\">",
"      Jatoi A, Rowland K, Sloan JA, et al. Tetracycline to prevent epidermal growth factor receptor inhibitor-induced skin rashes: results of a placebo-controlled trial from the North Central Cancer Treatment Group (N03CB). Cancer 2008; 113:847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35834/abstract/27\">",
"      Lee MW, Seo CW, Kim SW, et al. Cutaneous side effects in non-small cell lung cancer patients treated with Iressa (ZD1839), an inhibitor of epidermal growth factor. Acta Derm Venereol 2004; 84:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35834/abstract/28\">",
"      Dainichi T, Tanaka M, Tsuruta N, et al. Development of multiple paronychia and periungual granulation in patients treated with gefitinib, an inhibitor of epidermal growth factor receptor. Dermatology 2003; 207:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35834/abstract/29\">",
"      Eames T, Grabein B, Kroth J, Wollenberg A. Microbiological analysis of epidermal growth factor receptor inhibitor therapy-associated paronychia. J Eur Acad Dermatol Venereol 2010; 24:958.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35834/abstract/30\">",
"      Nowak AK, Byrne MJ. Cisplatin and gemcitabine in malignant mesothelioma. Ann Oncol 2005; 16:1711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35834/abstract/31\">",
"      Dueland S, Sauer T, Lund-Johansen F, et al. Epidermal growth factor receptor inhibition induces trichomegaly. Acta Oncol 2003; 42:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35834/abstract/32\">",
"      Pascual JC, Ba&ntilde;uls J, Belinchon I, et al. Trichomegaly following treatment with gefitinib (ZD1839). Br J Dermatol 2004; 151:1111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35834/abstract/33\">",
"      Luu M, Lai SE, Patel J, et al. Photosensitive rash due to the epidermal growth factor receptor inhibitor erlotinib. Photodermatol Photoimmunol Photomed 2007; 23:42.",
"     </a>",
"    </li>",
"    <li>",
"     www.fda.gov/medwatch/safety/2009/safety09.htm#Tarceva (Accessed on May 12, 2009).",
"    </li>",
"    <li>",
"     The RegiSCAR Project file://regiscar.uni-freiburg.de/index.html (Accessed on May 24, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35834/abstract/36\">",
"      Jatoi A, Nguyen PL. Do patients die from rashes from epidermal growth factor receptor inhibitors? A systematic review to help counsel patients about holding therapy. Oncologist 2008; 13:1201.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021743s14s16lbl.pdf (Accessed on October 16, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35834/abstract/38\">",
"      Trojan A, Jacky E, Follath F, Dummer R. Necrolytic migratory erythema (glucagenoma)-like skin lesions induced by EGF-receptor inhibition. Swiss Med Wkly 2003; 133:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35834/abstract/39\">",
"      Kurokawa I, Endo K, Hirabayashi M. Purpuric drug eruption possibly due to gefinitib (Iressa). Int J Dermatol 2005; 44:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35834/abstract/40\">",
"      Sheen YS, Hsiao CH, Chu CY. Severe purpuric xerotic dermatitis associated with gefitinib therapy. Arch Dermatol 2008; 144:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35834/abstract/41\">",
"      Lacouture ME. Mechanisms of cutaneous toxicities to EGFR inhibitors. Nat Rev Cancer 2006; 6:803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35834/abstract/42\">",
"      Tejwani A, Wu S, Jia Y, et al. Increased risk of high-grade dermatologic toxicities with radiation plus epidermal growth factor receptor inhibitor therapy. Cancer 2009; 115:1286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35834/abstract/43\">",
"      Budach W, B&ouml;lke E, Homey B. Severe cutaneous reaction during radiation therapy with concurrent cetuximab. N Engl J Med 2007; 357:514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35834/abstract/44\">",
"      B&ouml;lke E, Gerber PA, Lammering G, et al. Development and management of severe cutaneous side effects in head-and-neck cancer patients during concurrent radiotherapy and cetuximab. Strahlenther Onkol 2008; 184:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35834/abstract/45\">",
"      Skvortsova I. Oxidative damage and cutaneous reactions during radiotherapy in combination with cetuximab. Radiother Oncol 2009; 90:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35834/abstract/46\">",
"      Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006; 354:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35834/abstract/47\">",
"      Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344:1031.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35834/abstract/48\">",
"      Valeyrie L, Bastuji-Garin S, Revuz J, et al. Adverse cutaneous reactions to imatinib (STI571) in Philadelphia chromosome-positive leukemias: a prospective study of 54 patients. J Am Acad Dermatol 2003; 48:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35834/abstract/49\">",
"      Rule SA, O'Brien SG, Crossman LC. Managing cutaneous reactions to imatinib therapy. Blood 2002; 100:3434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35834/abstract/50\">",
"      Milojkovic D, Short K, Salisbury JR, et al. Dose-limiting dermatological toxicity secondary to imatinib mesylate (STI571) in chronic myeloid leukaemia. Leukemia 2003; 17:1414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35834/abstract/51\">",
"      Hsiao LT, Chung HM, Lin JT, et al. Stevens-Johnson syndrome after treatment with STI571: a case report. Br J Haematol 2002; 117:620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35834/abstract/52\">",
"      Tanvetyanon T, Nand S. Overcoming recurrent cutaneous reactions from imatinib using once-weekly dosing. Ann Pharmacother 2003; 37:1818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35834/abstract/53\">",
"      Schwarz M, Kreuzer KA, Baskaynak G, et al. Imatinib-induced acute generalized exanthematous pustulosis (AGEP) in two patients with chronic myeloid leukemia. Eur J Haematol 2002; 69:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35834/abstract/54\">",
"      Liu D, Seiter K, Mathews T, et al. Sweet's syndrome with CML cell infiltration of the skin in a patient with chronic-phase CML while taking Imatinib Mesylate. Leuk Res 2004; 28 Suppl 1:S61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35834/abstract/55\">",
"      Ayirookuzhi SJ, Ma L, Ramshesh P, Mills G. Imatinib-induced sweet syndrome in a patient with chronic myeloid leukemia. Arch Dermatol 2005; 141:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35834/abstract/56\">",
"      Sidoroff A, Halevy S, Bavinck JN, et al. Acute generalized exanthematous pustulosis (AGEP)--a clinical reaction pattern. J Cutan Pathol 2001; 28:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35834/abstract/57\">",
"      Roujeau JC, Bioulac-Sage P, Bourseau C, et al. Acute generalized exanthematous pustulosis. Analysis of 63 cases. Arch Dermatol 1991; 127:1333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35834/abstract/58\">",
"      Rousselot P, Larghero J, Raffoux E, et al. Photosensitization in chronic myelogenous leukaemia patients treated with imatinib mesylate. Br J Haematol 2003; 120:1091.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35834/abstract/59\">",
"      Tsao AS, Kantarjian H, Cortes J, et al. Imatinib mesylate causes hypopigmentation in the skin. Cancer 2003; 98:2483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35834/abstract/60\">",
"      Arora B, Kumar L, Sharma A, et al. Pigmentary changes in chronic myeloid leukemia patients treated with imatinib mesylate. Ann Oncol 2004; 15:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35834/abstract/61\">",
"      Leong KW, Lee TC, Goh AS. Imatinib mesylate causes hypopigmentation in the skin. Cancer 2004; 100:2486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35834/abstract/62\">",
"      Han H, Yu YY, Wang YH. Imatinib mesylate-induced repigmentation of vitiligo lesions in a patient with recurrent gastrointestinal stromal tumors. J Am Acad Dermatol 2008; 59:S80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35834/abstract/63\">",
"      Robert C, Soria JC, Spatz A, et al. Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol 2005; 6:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35834/abstract/64\">",
"      Longley BJ, Carter EL. SCF-KIT pathway in human epidermal melanocyte homeostasis. J Invest Dermatol 1999; 113:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35834/abstract/65\">",
"      Dickens E, Lewis F, Bienz N. Imatinib: a designer drug, another cutaneous complication. Clin Exp Dermatol 2009; 34:603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35834/abstract/66\">",
"      Woo SM, Huh CH, Park KC, Youn SW. Exacerbation of psoriasis in a chronic myelogenous leukemia patient treated with imatinib. J Dermatol 2007; 34:724.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35834/abstract/67\">",
"      Miyagawa S, Fujimoto H, Ko S, et al. Improvement of psoriasis during imatinib therapy in a patient with a metastatic gastrointestinal stromal tumour. Br J Dermatol 2002; 147:406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35834/abstract/68\">",
"      Drummond A, Micallef-Eynaud P, Douglas WS, et al. A spectrum of skin reactions caused by the tyrosine kinase inhibitor imatinib mesylate (STI 571, Glivec). Br J Haematol 2003; 120:911.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35834/abstract/69\">",
"      Battistella M, Fr&eacute;mont G, Vignon-Pennamen MD, et al. Imatinib-induced hand-foot syndrome in a patient with metastatic gastrointestinal stromal tumor. Arch Dermatol 2008; 144:1400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35834/abstract/70\">",
"      Heidary N, Naik H, Burgin S. Chemotherapeutic agents and the skin: An update. J Am Acad Dermatol 2008; 58:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35834/abstract/71\">",
"      Assouline S, Laneuville P, Gambacorti-Passerini C. Panniculitis during dasatinib therapy for imatinib-resistant chronic myelogenous leukemia. N Engl J Med 2006; 354:2623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35834/abstract/72\">",
"      Kantarjian H, Giles F, Wunderle L, et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 2006; 354:2542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35834/abstract/73\">",
"      Kantarjian HM, Giles F, Gattermann N, et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood 2007; 110:3540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35834/abstract/74\">",
"      Cortes JE, Kantarjian HM, Br&uuml;mmendorf TH, et al. Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib. Blood 2011; 118:4567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35834/abstract/75\">",
"      Cortes JE, Kim DW, Kantarjian HM, et al. Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial. J Clin Oncol 2012; 30:3486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35834/abstract/76\">",
"      Lacouture ME, Reilly LM, Gerami P, Guitart J. Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib. Ann Oncol 2008; 19:1955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35834/abstract/77\">",
"      Boone SL, Jameson G, Von Hoff D, Lacouture ME. Blackberry-induced hand-foot skin reaction to sunitinib. Invest New Drugs 2009; 27:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35834/abstract/78\">",
"      Tsai KY, Yang CH, Kuo TT, et al. Hand-foot syndrome and seborrheic dermatitis-like rash induced by sunitinib in a patient with advanced renal cell carcinoma. J Clin Oncol 2006; 24:5786.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35834/abstract/79\">",
"      Russell IJ, Perkins AT, Michalek JE, Oxybate SXB-26 Fibromyalgia Syndrome Study Group. Sodium oxybate relieves pain and improves function in fibromyalgia syndrome: a randomized, double-blind, placebo-controlled, multicenter clinical trial. Arthritis Rheum 2009; 60:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35834/abstract/80\">",
"      Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 356:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35834/abstract/81\">",
"      Autier J, Escudier B, Wechsler J, et al. Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor. Arch Dermatol 2008; 144:886.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35834/abstract/82\">",
"      Bhojani N, Jeldres C, Patard JJ, et al. Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma. Eur Urol 2008; 53:917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35834/abstract/83\">",
"      Chu D, Lacouture ME, Fillos T, Wu S. Risk of hand-foot skin reaction with sorafenib: a systematic review and meta-analysis. Acta Oncol 2008; 47:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35834/abstract/84\">",
"      Strumberg D, Awada A, Hirte H, et al. Pooled safety analysis of BAY 43-9006 (sorafenib) monotherapy in patients with advanced solid tumours: Is rash associated with treatment outcome? Eur J Cancer 2006; 42:548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35834/abstract/85\">",
"      Faivre S, Delbaldo C, Vera K, et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 2006; 24:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35834/abstract/86\">",
"      Azad NS, Aragon-Ching JB, Dahut WL, et al. Hand-foot skin reaction increases with cumulative sorafenib dose and with combination anti-vascular endothelial growth factor therapy. Clin Cancer Res 2009; 15:1411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35834/abstract/87\">",
"      Erber R, Thurnher A, Katsen AD, et al. Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms. FASEB J 2004; 18:338.",
"     </a>",
"    </li>",
"    <li>",
"     Azad NS, Annunziata C, Barrett T, et al. Dual targeting of vascular endothelial growth factor with sorafenib and bevacizumab: clinicalo and translational results (abstract). J Clin Oncol 2007; 25:148s. (abstract available online at www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&amp;vmview=abst_detail_view&amp;confID=47&amp;abstractID=32958, accessed December 11, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35834/abstract/89\">",
"      Lacouture ME, Wu S, Robert C, et al. Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib. Oncologist 2008; 13:1001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35834/abstract/90\">",
"      Arnault JP, Wechsler J, Escudier B, et al. Keratoacanthomas and squamous cell carcinomas in patients receiving sorafenib. J Clin Oncol 2009; 27:e59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35834/abstract/91\">",
"      Dubauskas Z, Kunishige J, Prieto VG, et al. Cutaneous squamous cell carcinoma and inflammation of actinic keratoses associated with sorafenib. Clin Genitourin Cancer 2009; 7:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35834/abstract/92\">",
"      Kong HH, Cowen EW, Azad NS, et al. Keratoacanthomas associated with sorafenib therapy. J Am Acad Dermatol 2007; 56:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35834/abstract/93\">",
"      Hong DS, Reddy SB, Prieto VG, et al. Multiple squamous cell carcinomas of the skin after therapy with sorafenib combined with tipifarnib. Arch Dermatol 2008; 144:779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35834/abstract/94\">",
"      Smith KJ, Haley H, Hamza S, Skelton HG. Eruptive keratoacanthoma-type squamous cell carcinomas in patients taking sorafenib for the treatment of solid tumors. Dermatol Surg 2009; 35:1766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35834/abstract/95\">",
"      Kwon EJ, Kish LS, Jaworsky C. The histologic spectrum of epithelial neoplasms induced by sorafenib. J Am Acad Dermatol 2009; 61:522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35834/abstract/96\">",
"      Jantzem H, Dupre-Goetghebeur D, Spindler P, Merrer J. [Sorafenib-induced multiple eruptive keratoacanthomas]. Ann Dermatol Venereol 2009; 136:894.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35834/abstract/97\">",
"      Rini BI, Escudier B, Tomczak P, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 2011; 378:1931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35834/abstract/98\">",
"      Kong HH, Sibaud V, Chanco Turner ML, et al. Sorafenib-induced eruptive melanocytic lesions. Arch Dermatol 2008; 144:820.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35834/abstract/99\">",
"      Suwattee P, Chow S, Berg BC, Warshaw EM. Sunitinib: a cause of bullous palmoplantar erythrodysesthesia, periungual erythema, and mucositis. Arch Dermatol 2008; 144:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35834/abstract/100\">",
"      Robert C, Mateus C, Spatz A, et al. Dermatologic symptoms associated with the multikinase inhibitor sorafenib. J Am Acad Dermatol 2009; 60:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35834/abstract/101\">",
"      Nadauld LD, Miller MB, Srinivas S. Pyoderma gangrenosum with the use of sunitinib. J Clin Oncol 2011; 29:e266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35834/abstract/102\">",
"      Dean SM, Zirwas M. A Second Case of Sunitinib-associated Pyoderma Gangrenosum. J Clin Aesthet Dermatol 2010; 3:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35834/abstract/103\">",
"      ten Freyhaus K, Homey B, Bieber T, Wilsmann-Theis D. Pyoderma gangrenosum: another cutaneous side-effect of sunitinib? Br J Dermatol 2008; 159:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35834/abstract/104\">",
"      Degen A, Satzger I, Voelker B, et al. Does basal cell carcinoma belong to the spectrum of sorafenib-induced epithelial skin cancers? Dermatology 2010; 221:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35834/abstract/105\">",
"      Sternberg CN, Davis ID, Mardiak J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010; 28:1061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35834/abstract/106\">",
"      Sideras K, Menefee ME, Burton JK, et al. Profound hair and skin hypopigmentation in an African American woman treated with the multi-targeted tyrosine kinase inhibitor pazopanib. J Clin Oncol 2010; 28:e312.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022465s002lbl.pdf (Accessed on September 22, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35834/abstract/108\">",
"      Balagula Y, Wu S, Su X, et al. The risk of hand foot skin reaction to pazopanib, a novel multikinase inhibitor: a systematic review of literature and meta-analysis. Invest New Drugs 2012; 30:1773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35834/abstract/109\">",
"      Fischer A, Wu S, Ho AL, Lacouture ME. The risk of hand-foot skin reaction to axitinib, a novel VEGF inhibitor: a systematic review of literature and meta-analysis. Invest New Drugs 2013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35834/abstract/110\">",
"      Wells SA Jr, Gosnell JE, Gagel RF, et al. Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Oncol 2010; 28:767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35834/abstract/111\">",
"      Robinson BG, Paz-Ares L, Krebs A, et al. Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Endocrinol Metab 2010; 95:2664.",
"     </a>",
"    </li>",
"    <li>",
"     Wells, SA, Robinson, BG, Gagel, RRF, et al. Vandetanib (VAN) in locally advanced or metastatic medullary thyroid cancer (MTC): A randomized, double-blind phase III trial (ZETA) (Abstract 5503). J Cliin Oncol 2010; 28:421s. Abstract available online at file://www.asco.org/ASCOv2/Meetings/Abstracts?&amp;vmview=abst_detail_view&amp;confID=74&amp;abstractID=50718 (Accessed on April 25, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35834/abstract/113\">",
"      Natale RB, Thongprasert S, Greco FA, et al. Phase III trial of vandetanib compared with erlotinib in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol 2011; 29:1059.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35834/abstract/114\">",
"      Arnold AM, Seymour L, Smylie M, et al. Phase II study of vandetanib or placebo in small-cell lung cancer patients after complete or partial response to induction chemotherapy with or without radiation therapy: National Cancer Institute of Canada Clinical Trials Group Study BR.20. J Clin Oncol 2007; 25:4278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35834/abstract/115\">",
"      Lee JS, Hirsh V, Park K, et al. Vandetanib Versus placebo in patients with advanced non-small-cell lung cancer after prior therapy with an epidermal growth factor receptor tyrosine kinase inhibitor: a randomized, double-blind phase III trial (ZEPHYR). J Clin Oncol 2012; 30:1114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35834/abstract/116\">",
"      Giacchero D, Ramacciotti C, Arnault JP, et al. A new spectrum of skin toxic effects associated with the multikinase inhibitor vandetanib. Arch Dermatol 2012; 148:1418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35834/abstract/117\">",
"      Yoon J, Oh CW, Kim CY. Stevens-johnson syndrome induced by vandetanib. Ann Dermatol 2011; 23:S343.",
"     </a>",
"    </li>",
"    <li>",
"     US FDA-approved manufacturere's labeling information for vandetanib, available online at file://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4dc7f0af-77fb-4eec-46b9-dd1c2dcb4525 (Accessed on December 10, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35834/abstract/119\">",
"      Grothey A, Van Cutsem E, Sobrero A, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 2013; 381:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35834/abstract/120\">",
"      Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364:2507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35834/abstract/121\">",
"      Ribas A, Kim KB, Schuchter LM, et al. BRIM-2: An open-label, multicenter phase II study of vemurafenib in previously treated patients with BRAF V600E mutation-positive metastatic melanoma. J Clin Oncol 2011; 29: Abstract 8509.",
"     </a>",
"    </li>",
"    <li>",
"     Zelboraf (vemurafenib) prescribing information www.accessdata.fda.gov/drugsatfda_docs/label/2011/202429s000lbl.pdf (Accessed on October 11, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35834/abstract/123\">",
"      Dummer R, Rinderknecht J, Goldinger SM. Ultraviolet A and photosensitivity during vemurafenib therapy. N Engl J Med 2012; 366:480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35834/abstract/124\">",
"      Payne AS, James WD, Weiss RB. Dermatologic toxicity of chemotherapeutic agents. Semin Oncol 2006; 33:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35834/abstract/125\">",
"      Gotlib V, Khaled S, Lapko I, et al. Skin rash secondary to bevacizumab in a patient with advanced colorectal cancer and relation to response. Anticancer Drugs 2006; 17:1227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35834/abstract/126\">",
"      Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003; 349:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35834/abstract/127\">",
"      Di Giacomo AM, Biagioli M, Maio M. The emerging toxicity profiles of anti-CTLA-4 antibodies across clinical indications. Semin Oncol 2010; 37:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35834/abstract/128\">",
"      Cort&eacute;s J, Fumoleau P, Bianchi GV, et al. Pertuzumab monotherapy after trastuzumab-based treatment and subsequent reintroduction of trastuzumab: activity and tolerability in patients with advanced human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 2012; 30:1594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35834/abstract/129\">",
"      Baselga J, Cort&eacute;s J, Kim SB, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 2012; 366:109.",
"     </a>",
"    </li>",
"    <li>",
"     Wyeth. Gemtuzumab prescribing information 2007.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35834/abstract/131\">",
"      Osterborg A, Karlsson C, Lundin J, et al. Strategies in the management of alemtuzumab-related side effects. Semin Oncol 2006; 33:S29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35834/abstract/132\">",
"      Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363:711.",
"     </a>",
"    </li>",
"    <li>",
"     FDA approved package insert file://www.accessdata.fda.gov/drugsatfda_docs/label/2011/125377s0000lbl.pdf.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35834/abstract/134\">",
"      Passweg J, Buser U, Tichelli A, et al. Pustular eruption at the site of subcutaneous injection of recombinant human granulocyte-macrophage colony-stimulating factor. Ann Hematol 1991; 63:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35834/abstract/135\">",
"      Asnis LA, Gaspari AA. Cutaneous reactions to recombinant cytokine therapy. J Am Acad Dermatol 1995; 33:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35834/abstract/136\">",
"      Wolkenstein P, Chosidow O, Wechsler J, et al. Cutaneous side effects associated with interleukin 2 administration for metastatic melanoma. J Am Acad Dermatol 1993; 28:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35834/abstract/137\">",
"      Staunton MR, Scully MC, Le Boit PE, Aronson FR. Life-threatening bullous skin eruptions during interleukin-2 therapy. J Natl Cancer Inst 1991; 83:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/63/35834/abstract/138\">",
"      Wiener JS, Tucker JA Jr, Walther PJ. Interleukin-2-induced dermatotoxicity resembling toxic epidermal necrolysis. South Med J 1992; 85:656.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2088 Version 17.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-197.136.42.3-87592D432B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_63_35834=[""].join("\n");
var outline_f34_63_35834=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H757138\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EGFR SIGNAL TRANSDUCTION INHIBITORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Acneiform eruption",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Prophylactic therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H21260792\">",
"      Topical anti-acne therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H21260800\">",
"      Systemic antibiotics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Other reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      SMALL MOLECULE KINASE SIGNAL TRANSDUCTION INHIBITORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Imatinib",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10106591\">",
"      Dasatinib, nilotinib, and bosutinib",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Sorafenib and sunitinib",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Hand-foot skin reaction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Squamoproliferative lesions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Other effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H91378765\">",
"      Pazopanib",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31257041\">",
"      Axitinib",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22183968\">",
"      Vandetanib",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11564980\">",
"      Regorafenib",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3204039\">",
"      Vemurafenib",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      OTHER THERAPEUTIC MONOCLONAL ANTIBODIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Infusion reactions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Serum sickness",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Other reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      CYTOKINE AGENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Colony stimulating factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Interferons",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Interleukin-2",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H757138\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DERM/2088\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/2088|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?21/20/21827\" title=\"picture 1\">",
"      EGFR inhbtr acneiform erupt",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?13/30/13796\" title=\"picture 2\">",
"      EGFR inhibitor paronychia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?32/35/33328\" title=\"picture 3\">",
"      Sorafenib HFSR",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/2088|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?6/2/6187\" title=\"table 1\">",
"      Cutan react EGFR inhib",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?36/61/37851\" title=\"table 2\">",
"      Cetuximab dose modify derm tox",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?7/45/7900\" title=\"table 3\">",
"      Cutan react multitarg TKI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?9/56/10123\" title=\"table 4\">",
"      Grading HFSR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?8/51/9019\" title=\"table 5\">",
"      Broad spectrum sunscreens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?3/4/3147\" title=\"table 6\">",
"      Cutan react mono antibod",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?13/23/13692\" title=\"table 7\">",
"      Types of allergic reactions",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/28/2506?source=related_link\">",
"      Advanced melanoma: anti-CTLA-4 antibodies and other immune checkpoint strategies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/7/36986?source=related_link\">",
"      Cutaneous complications of conventional chemotherapy agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/19/38202?source=related_link\">",
"      Infusion reactions to therapeutic monoclonal antibodies used for cancer therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/4/31816?source=related_link\">",
"      Initial systemic therapy for advanced non-small cell lung cancer with a mutation in the epidermal growth factor receptor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/55/7034?source=related_link\">",
"      Initial treatment of chronic myeloid leukemia in chronic phase",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/15/29946?source=related_link\">",
"      Locally advanced squamous cell carcinoma of the head and neck: Approaches combining chemotherapy and radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/30/19944?source=related_link\">",
"      Molecularly targeted therapy for metastatic melanoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/40/8842?source=related_link\">",
"      Serum sickness and serum sickness-like reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/32/44554?source=related_link\">",
"      Systemic chemotherapy for metastatic colorectal cancer: Completed clinical trials",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/27/11705?source=related_link\">",
"      Systemic treatment for metastatic breast cancer: Combination chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/30/31209?source=related_link\">",
"      Treatment and prognosis of cutaneous squamous cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/17/20762?source=related_link\">",
"      Treatment of chronic myeloid leukemia in chronic phase after failure of initial therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/58/34730?source=related_link\">",
"      Tyrosine kinase inhibitor therapy for advanced gastrointestinal stromal tumors",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_63_35835="Effects of OA PI";
var content_f34_63_35835=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F77930&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F77930&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Effects of osteoarthritis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Age when symptoms start",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Usually after 40",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Commonly affected body parts",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Neck and lower back",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Joint at the base of the thumb",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Knuckles in the middle and near the tip of the fingers",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hip",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Knee",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Joint in the foot, above the heel",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Knuckle at the base of the big toe",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Less commonly affected body parts",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Shoulder",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Wrist",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Elbow",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Knuckles at the base of the fingers",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Symptoms",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pain",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stiffness",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Crackling or clicking sounds in the joints",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Extra bone growth (for example, knuckles that look swollen or knobby)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Decreased range of motion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Problems with the alignment of certain joints",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tenderness to the touch",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_63_35835=[""].join("\n");
var outline_f34_63_35835=null;
var title_f34_63_35836="HBV cirrhosis and HCC";
var content_f34_63_35836=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F67001&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F67001&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hepatocellular carcinoma in HBV-related cirrhosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 359px; height: 230px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Cumulative probability of developing hepatocellular carcinoma in patients with compensated cirrhosis related to hepatitis B virus (HBV) infection.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Fattovich G, Giustina G, Schalm SW, et al. Hepatology 1995; 21:77.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_63_35836=[""].join("\n");
var outline_f34_63_35836=null;
var title_f34_63_35837="Acute and late oral complications associated with cancer therapy";
var content_f34_63_35837=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F85779&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=11\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F85779&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=11\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Acute and late oral complications associated with cancer therapy",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup width=\"10%\">",
"     </colgroup>",
"     <colgroup width=\"20%\">",
"     </colgroup>",
"     <colgroup span=\"2\" width=\"35%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Complication",
"       </td>",
"       <td class=\"subtitle1\">",
"        Patients at risk",
"       </td>",
"       <td class=\"subtitle1\">",
"        Considerations",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"4\">",
"        <strong>",
"         Acute",
"        </strong>",
"       </td>",
"       <td>",
"        Oral infection (viral, bacterial and fungal)",
"       </td>",
"       <td>",
"        <ul>",
"         <li>",
"          Intensive high-dose chemotherapy regimens",
"         </li>",
"         <li>",
"          Head and neck radiation",
"         </li>",
"        </ul>",
"       </td>",
"       <td>",
"        <ul>",
"         <li>",
"          Odontogenic infections may present with pain/fever but without cardinal signs of erythema and purulence",
"         </li>",
"         <li>",
"          Intraoral HSV recrudescence may affect keratinized and non-keratinized mucosal sites",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Oral mucositis",
"       </td>",
"       <td>",
"        <ul>",
"         <li>",
"          Intensive high-dose chemotherapy regimens",
"         </li>",
"         <li>",
"          Head and neck radiation",
"         </li>",
"         <li>",
"          mTOR inhibitor therapy",
"         </li>",
"        </ul>",
"       </td>",
"       <td>",
"        <ul>",
"         <li>",
"          Starts 7 to 10 days after chemotherapy, resolves within three weeks",
"         </li>",
"         <li>",
"          Peaks after third week of radiation, resolves weeks after completion of therapy",
"         </li>",
"         <li>",
"          mTOR inhibitor stomatitis appears aphthous-like, develops within first week of therapy",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Salivary dysfunction",
"       </td>",
"       <td>",
"        <ul>",
"         <li>",
"          Head and neck radiation",
"         </li>",
"        </ul>",
"       </td>",
"       <td>",
"        <ul>",
"         <li>",
"          Oral burning common",
"         </li>",
"         <li>",
"          Increased risk of candidiasis",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Oral hemorrhage",
"       </td>",
"       <td>",
"        <ul>",
"         <li>",
"          Thrombocytopenia secondary to chemotherapy",
"         </li>",
"        </ul>",
"       </td>",
"       <td>",
"        <ul>",
"         <li>",
"          Appears in the oral cavity as areas of active bleeding, petechiae, or ecchymosis",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"7\">",
"        <strong>",
"         Late",
"        </strong>",
"       </td>",
"       <td>",
"        Chronic GVHD",
"       </td>",
"       <td>",
"        <ul>",
"         <li>",
"          Patients who received allogeneic hematopoietic cell transplantation",
"         </li>",
"        </ul>",
"       </td>",
"       <td>",
"        <ul>",
"         <li>",
"          Typically appears after day +100",
"         </li>",
"         <li>",
"          Reticulation, erythema and/or ulcerations, primarily affecting the tongue and buccal mucosa",
"         </li>",
"         <li>",
"          Superficial mucoceles of the palate",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Jaw osteonecrosis",
"       </td>",
"       <td>",
"        <ul>",
"         <li>",
"          Anti-resorptive therapy",
"         </li>",
"         <li>",
"          Head and neck radiation",
"         </li>",
"        </ul>",
"       </td>",
"       <td>",
"        <ul>",
"         <li>",
"          Characterized by exposed necrotic bone in the oral cavity",
"         </li>",
"         <li>",
"          Symptoms usually due to secondary soft tissue infection",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Taste dysfunction",
"       </td>",
"       <td>",
"        <ul>",
"         <li>",
"          Head and neck radiation",
"         </li>",
"         <li>",
"          Chemotherapy",
"         </li>",
"         <li>",
"          Chronic GVHD",
"         </li>",
"        </ul>",
"       </td>",
"       <td>",
"        <ul>",
"         <li>",
"          Typically recovers after several months",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Trismus",
"       </td>",
"       <td>",
"        <ul>",
"         <li>",
"          Head and neck surgery",
"         </li>",
"         <li>",
"          Head and neck radiation",
"         </li>",
"         <li>",
"          Chronic GVHD",
"         </li>",
"        </ul>",
"       </td>",
"       <td>",
"        <ul>",
"         <li>",
"          Develops gradually over time",
"         </li>",
"         <li>",
"          Maintaining oral hygiene and providing dental care can be challenging",
"         </li>",
"         <li>",
"          Requires long-term physical therapy",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Impairment of craniofacial development in children",
"       </td>",
"       <td>",
"        <ul>",
"         <li>",
"          Chemotherapy or head and neck radiation at a young age",
"         </li>",
"        </ul>",
"       </td>",
"       <td>",
"        <ul>",
"         <li>",
"          Dental abnormalities include delayed eruption of teeth, microdontia, and tooth agenesis",
"         </li>",
"         <li>",
"          Bone abnormalities include deficient head and neck skeletal growth",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Salivary dysfunction",
"       </td>",
"       <td>",
"        <ul>",
"         <li>",
"          Head and neck radiation",
"         </li>",
"         <li>",
"          Chronic GVHD",
"         </li>",
"        </ul>",
"       </td>",
"       <td>",
"        <ul>",
"         <li>",
"          Oral burning common",
"         </li>",
"         <li>",
"          Increased risk of candidiasis and dental caries",
"         </li>",
"         <li>",
"          Prescription and non-prescription management",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Oral squamous cell carcinoma",
"       </td>",
"       <td>",
"        <ul>",
"         <li>",
"          History of head and neck cancer",
"         </li>",
"         <li>",
"          Recipients of allogeneic hematopoietic cell transplantation",
"         </li>",
"        </ul>",
"       </td>",
"       <td>",
"        <ul>",
"         <li>",
"          Field cancerization changes increase risk of new primary lesions",
"         </li>",
"         <li>",
"          Well-defined, abnormal mucosal lesions, require biopsy for diagnosis",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     HSV: herpes simplex virus; mTOR: mammalian target of rapamycin; GVHD: graft versus host disease.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_63_35837=[""].join("\n");
var outline_f34_63_35837=null;
var title_f34_63_35838="Endoscopy nasal cavity";
var content_f34_63_35838=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F59556&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F59556&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Endoscopic view of the nose",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 326px; height: 314px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Endoscopic view of the right nasal cavity showing purulent discharge flowing from the maxillary and ethmoid sinuses onto the middle&nbsp;meatus. The middle turbinate&nbsp;(MT), lateral nasal wall (L), and nasal septum (S) are visible.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_63_35838=[""].join("\n");
var outline_f34_63_35838=null;
var title_f34_63_35839="Contents: Adult orthopedics";
var content_f34_63_35839=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"mobipreview.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"mobipreview.htm?1/34/1568\">",
"       Family Medicine and General Practice",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Adult orthopedics",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"mobipreview.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Adult orthopedics",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Ankle and foot",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?31/49/32537\">",
"           Achilles tendinopathy and tendon rupture",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?33/31/34296\">",
"           Ankle sprain",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?1/58/1960\">",
"           Hallux valgus deformity (bunion)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?43/40/44681\">",
"           Plantar fasciitis and other causes of heel pain",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?1/0/1030\">",
"           Posterior and medial ankle tendinopathies not involving the Achilles tendon",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Elbow",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?1/20/1354\">",
"           Epicondylitis (tennis and golf elbow)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?14/40/14983\">",
"           Evaluation of elbow pain in adults",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Fractures",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?28/36/29251\">",
"           Capitate fractures",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?12/43/12985\">",
"           Clavicle fractures",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?14/7/14458\">",
"           Clinical manifestations and treatment of osteoporotic thoracolumbar vertebral compression fractures",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?41/13/42197\">",
"           Distal phalanx fractures",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?21/13/21722\">",
"           Distal radius fractures in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?26/6/26726\">",
"           Fibular fractures",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?17/26/17828\">",
"           First (thumb) metacarpal fractures",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?16/58/17318\">",
"           General principles of acute fracture management",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?1/23/1400\">",
"           General principles of definitive fracture management",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?42/58/43941\">",
"           General principles of fracture management: Bone healing and fracture description",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?6/42/6823\">",
"           General principles of fracture management: Early and late complications",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?9/25/9620\">",
"           Hamate fractures",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?18/31/18937\">",
"           Hip fractures in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?4/17/4376\">",
"           Initial evaluation and management of rib fractures",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?23/61/24531\">",
"           Lunate fractures",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?22/9/22675\">",
"           Metacarpal base fractures",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?22/11/22707\">",
"           Metacarpal head fractures",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?13/4/13382\">",
"           Metacarpal neck fractures",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?20/5/20565\">",
"           Metacarpal shaft fractures",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?12/20/12614\">",
"           Metatarsal shaft fractures",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?39/59/40885\">",
"           Middle phalanx fractures",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?40/62/41960\">",
"           Midshaft femur fractures in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?26/55/27510\">",
"           Midshaft humeral fractures in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?35/33/36376\">",
"           Overview of ankle fractures in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?4/49/4886\">",
"           Overview of carpal fractures",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?2/6/2149\">",
"           Overview of metacarpal fractures",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?23/19/23866\">",
"           Overview of stress fractures",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?25/47/26358\">",
"           Overview of tibial fractures in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?20/42/21157\">",
"           Patella fractures",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?36/22/37218\">",
"           Pisiform fractures",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?0/54/873\">",
"           Proximal fifth metatarsal fractures",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?28/54/29543\">",
"           Proximal humeral fractures in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?19/36/20037\">",
"           Proximal phalanx fractures",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?5/52/5957\">",
"           Proximal tibial fractures in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?32/4/32838\">",
"           Radial head and neck fractures in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?1/51/1848\">",
"           Scaphoid fractures",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?27/52/28485\">",
"           Sesamoid fractures of the foot",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?42/50/43812\">",
"           Stress fractures of the humeral shaft",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?32/61/33747\">",
"           Stress fractures of the metatarsal shaft",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?19/4/19527\">",
"           Stress fractures of the tibia and fibula",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?30/4/30790\">",
"           Tibial shaft fractures in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?43/20/44358\">",
"           Toe fractures in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?36/3/36915\">",
"           Trapezium fractures",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?32/39/33394\">",
"           Trapezoid fractures",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?35/55/36723\">",
"           Triquetral fractures",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         General topics",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?25/48/26375\">",
"           Burners (stingers): Acute brachial plexus injury in the athlete",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?13/45/14041\">",
"           Bursitis: An overview of clinical manifestations, diagnosis, and management",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?3/7/3193\">",
"           Diagnostic imaging of joint pain",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?31/37/32344\">",
"           Etiology, clinical manifestations, and diagnosis of complex regional pain syndrome in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?28/14/28904\">",
"           Evaluation of the adult with monoarticular pain",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?33/15/34039\">",
"           Evaluation of the adult with polyarticular pain",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?16/58/17318\">",
"           General principles of acute fracture management",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?1/23/1400\">",
"           General principles of definitive fracture management",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?42/58/43941\">",
"           General principles of fracture management: Bone healing and fracture description",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?2/10/2215\">",
"           Overview of overuse (chronic) tendinopathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?19/39/20089\">",
"           Overview of the management of overuse (chronic) tendinopathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?14/54/15208\">",
"           Splinting of musculoskeletal injuries",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Hand",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?38/54/39783\">",
"           Dupuytren's contracture",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?25/17/25879\">",
"           Evaluation of the patient with hand pain",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?9/44/9928\">",
"           Evaluation of the patient with thumb pain",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?37/31/38390\">",
"           Extensor tendon injury of the distal interphalangeal joint (mallet finger)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?41/41/42645\">",
"           Finger and thumb anatomy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?27/58/28581\">",
"           Flexor tendon injury of the distal interphalangeal joint (jersey finger)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?18/44/19141\">",
"           Trigger finger (stenosing flexor tenosynovitis)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?31/20/32068\">",
"           Ulnar collateral ligament injury (gamekeeper's or skier's thumb)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?26/40/27270\">",
"           de Quervain's tenosynovitis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Hip",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?1/39/1658\">",
"           Complications of total hip arthroplasty",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?21/36/22088\">",
"           Evaluation of the adult with hip pain",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?18/31/18937\">",
"           Hip fractures in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?38/9/39061\">",
"           Meralgia paresthetica (lateral femoral cutaneous nerve entrapment)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?24/39/25210\">",
"           Radiologic evaluation of the painful hip in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?9/55/10106\">",
"           Total hip arthroplasty",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?18/33/18966\">",
"           Trochanteric bursitis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Knee",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?31/24/32138\">",
"           Anterior cruciate ligament injury",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?16/32/16902\">",
"           Complications of total knee arthroplasty",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?6/29/6618\">",
"           Evaluation of the active adult patient with knee pain",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?27/48/28422\">",
"           Knee bursitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?3/11/3257\">",
"           Medial collateral ligament injury of the knee",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?16/15/16632\">",
"           Meniscal injury of the knee",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?42/61/43993\">",
"           Patellofemoral pain syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?27/57/28565\">",
"           Synovectomy for inflammatory arthritis of the knee",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?17/6/17514\">",
"           Total knee arthroplasty",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Lower extremity",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?14/35/14906\">",
"           Hamstring injuries",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?34/4/34890\">",
"           Overview of running injuries of the lower extremity",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Neck",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?1/24/1418\">",
"           Evaluation of the patient with neck pain and cervical spine disorders",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?22/36/23113\">",
"           Treatment of neck pain",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Shoulder",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?43/25/44439\">",
"           Acromioclavicular joint disorders",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?10/26/10663\">",
"           Acromioclavicular joint injuries",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?25/24/25991\">",
"           Biceps tendinopathy and tendon rupture",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?12/43/12985\">",
"           Clavicle fractures",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?35/7/35961\">",
"           Evaluation of the patient with shoulder complaints",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?33/7/33912\">",
"           Frozen shoulder (adhesive capsulitis)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?26/0/26630\">",
"           Glenohumeral osteoarthritis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?24/32/25095\">",
"           Management of rotator cuff tears",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?40/39/41592\">",
"           Multidirectional instability of the shoulder",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?27/11/27834\">",
"           Physical examination of the shoulder",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?6/46/6887\">",
"           Presentation and diagnosis of rotator cuff tears",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?35/36/36425\">",
"           Radiologic evaluation of the painful shoulder",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?12/63/13305\">",
"           Rehabilitation principles and practice in shoulder impingement syndromes",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?20/50/21289\">",
"           Rotator cuff tendinopathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?10/8/10378\">",
"           Shoulder dislocation and reduction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?31/33/32280\">",
"           Shoulder impingement syndrome",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Sports medicine",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?27/35/28215\">",
"           Chronic exertional compartment syndrome",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Wrist",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?13/45/14039\">",
"           Anatomy and basic biomechanics of the wrist",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?41/15/42230\">",
"           Clinical manifestations and diagnosis of carpal tunnel syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?23/22/23911\">",
"           Etiology of carpal tunnel syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?12/21/12632\">",
"           Evaluation of the adult with acute wrist pain",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?19/52/20298\">",
"           Evaluation of the adult with subacute or chronic wrist pain",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?40/16/41223\">",
"           Ganglia and nodules",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?32/3/32822\">",
"           Surgery for carpal tunnel syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?42/62/44008\">",
"           Treatment of carpal tunnel syndrome",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-CBADBA5CDB-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f34_63_35839=[""].join("\n");
var outline_f34_63_35839=null;
